

**REMARKS/ARGUMENTS**

Claims 1, 4-13, and 15-18 are pending. Applicants thank the Examiner for withdrawal of the rejection under 35 U.S.C. §112, second paragraph.

**I. Status of the claims**

Claim 1 is amended to recite conditions associated with fetal alcohol syndrome (FAS) that are reduced by treatment with ADNF peptides. Support for this amendment is found throughout the specification, for example at page 7, lines 19-27; page 17, lines 1-4, and original claims 15-18. This amendment adds no new matter.

New claim 45 is directed to the method of claim 1 using a mixture of an ADNF I polypeptide of SEQ ID NO:1 and an ADNF III polypeptide of SEQ ID NO:2. Support for this amendment is found throughout the specification, for example at page 3, line 30 through page 4, line 5; Figures 1-3 and their respective figure legends at page 5, lines 1-30; and page 17, lines 8-13. This amendment adds no new matter.

New claim 46 is directed to the method of claim 1 with the limitation that the ADNF polypeptide is administered before alcohol exposure. Support for this amendment is found throughout the specification, for example at Figures 1-3 and respective figure legends at page 5, lines 1-30; page 35, line 24 through page 36, line 3; and page 37, lines 1-10. This amendment adds no new matter.

**II. Rejections under 35 U.S.C. §112, first paragraph enablement.**

Claims 1, 4-13, and 15-18 are rejected under 35 U.S.C. §112, first paragraph for allegedly lacking enablement. In order to expedite prosecution Applicants have amended claim 1 to recite conditions associated with fetal alcohol syndrome (FAS) that are reduced by treatment with ADNF peptides. This amendment adds no new matter. However, the Office Action also alleges that the specification does not provide enablement for ADNF polypeptide dosages and timing of administration, in particular for administration of ADNF polypeptides after exposure to alcohol.

Applicants respectfully traverse the rejection. The test of enablement is “whether one skilled in the art could make or use the claimed invention from the disclosure in the patent coupled with information known in the art without undue experimentation” (*see, e.g.*, MPEP §2164.01). In addition, claims reading on inoperative embodiments are enabled if the skilled artisan understands how to avoid inoperative embodiments. (*See, In re Cook and Merigold*, 169 USPQ 299, 301 (C.C.P.A. 1971)).

The specification discloses methods to determine the dosage and timing of ADNF polypeptides using, at most, routine experimentation. Methods to determine dosage and timing of administration of ADNF polypeptides generally are found at page 19, lines 23-29. An art accepted mouse model is specifically exemplified for administration of ADNF polypeptides to reduce conditions associated with FAS in the Examples section, *see e.g.*, page 32, line 27 through page 33, line 5. In addition, dosages for the model system are given at page 19, lines 20-22, with the recognition that one of skill could extrapolate to an appropriate dosage for a human subject.

In a response filed December 26, 2001, Applicants submitted a post-filing reference authored by the inventors demonstrating that the methods disclosed in the application can be routinely varied by one of skill and used to determine dosage and timing of administration of ADNF polypeptides, including time points following ethanol exposure. The reference demonstrates that the same methods disclosed in the application, with minor changes in timing of administration of ADNF relative to ethanol exposure, can be used to determine dosage and timing of administration of ADNF polypeptides after ethanol exposure. For example, the reference shows that fetal demise is decreased when ADNF polypeptides are administered one hour after ethanol exposure, but that fetal demise is not affected by administration of ADNF polypeptides three hours after ethanol exposure. Thus, one of skill would be able to routinely use the disclosed methods to determine the appropriate dosage and timing of administration of ADNF polypeptides both before and after ethanol administration. Without admitting a lack of operation at the three hour time point under all conditions, Applicants also assert that the

Appl. No. 09/267,511  
Amdt. dated July 22, 2003  
Amendment under 37 CFR 1.116 Expedited  
Procedure Examining Group

PATENT

reference demonstrates that one of skill would be able to use the disclosed methods to identify inoperative embodiments of the claimed invention.

Finally, Applicants have also submitted a declaration of Dr. Douglas Brenneman, an inventor, asserting that treatment with ADNF polypeptides is effective in reducing conditions associated with fetal alcohol syndrome when given before or after administration of alcohol, and that one of skill in the art can practice the claimed methods using information provided in the specification, together with methodology known to one of skill in the art, with at most, only routine experimentation.

Given the disclosure in the application as filed, the post-filing experimental data, and the declaration of Dr. Brenneman, Applicants assert that the claims as written are fully enabled by the specification. Applicants, thus, respectfully request that the rejection for alleged lack of enablement be withdrawn.

### CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is urged.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

  
Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
BLK:blk  
11462788 v1

## CURRICULUM VITAE

Douglas E. Brenneman

Born: April 21, 1946. Lincoln, Nebraska  
Married, 2 children

1964-1965 Hesston College, Hesston, Kansas.

1965-1968 B.A. Natural Science, Goshen College, Goshen, Indiana.

1968-1971 Research Fellow, Lipid Metabolism, Department of Internal Medicine, University of Iowa, Iowa City, Iowa.

1971-1976 Research Assistant, Department of Biochemistry, University of Iowa, Iowa City, Iowa.

1976-1980 M.S., Ph.D.(Honors) Pharmacology and Toxicology, University of Kansas, Lawrence, Kansas.

1980-1982 PRAT Postdoctoral Fellowship, Laboratory of Developmental Neurobiology, National Institute of General Medical Sciences, NIH, Bethesda, Maryland.

1982-1987 Senior Staff Fellow, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.

1987- 1992 Staff Pharmacologist and Head of Unit on Neurochemistry, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.

1992- Present Chief, Section on Developmental and Molecular Pharmacology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.

## Publications

1. Brenneman, D.E., W.E. Connor, E.L. Forker and L. DenBesten. The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. *J. Clin. Invest.* 51: 1495-1503, 1972.
2. Spector, A.A. and D.E. Brenneman. Effect of free fatty acid structure on binding to rat liver mitochondria. *Biochim. Biophys. Acta* 260: 433-438, 1972.
3. Spector, A.A. and D.E. Brenneman. Role of free fatty acids and lipoproteins in the lipid nutrition of tumor cells. In *Tumor Lipids: Biochemistry and Metabolism*. R. Wood, editor. American Oil Chemists' Society, Champaign, Ill. 1-13, 1972.
4. Brenneman, D.E. and A.A. Spector. Uptake of ascites plasma very low density lipoprotein triglycerides by Ehrlich cells. *J. Lipid Res.* 15: 309-316, 1974.
5. Brenneman, D.E., R. McGee and A.A. Spector. Cholesterol metabolism in the Ehrlich ascites tumor. *Cancer Res.* 34: 2605-2611, 1974.
6. Brenneman, D.E., S.N. Mathur and A.A. Spector. Characterization of the hyperlipidemia in mice bearing the Ehrlich Ascites tumor. *Europ. J. Cancer* 11: 225-230, 1975.
7. Brenneman, D.E., R. McGee, V. Liepkalns and A.A. Spector. Cholestryl ester accumulation in Ehrlich cells induced by saturated fats. *Biochim. Biophys. Acta* 388: 301-304, 1975.
8. McGee, R., D.E. Brenneman and A.A. Spector. Regulation of fatty acid biosynthesis in Ehrlich cells by ascites tumor plasma lipoproteins. *Lipids* 12: 66-74, 1977.
9. Brenneman, D.E., T. Kaduce and A.A. Spector. Effect of dietary fat saturation on acylcoenzyme A cholesterol acyltransferase activity of Ehrlich cell membranes. *J. Lipid Res.* 18: 582-591, 1977.
10. Brenneman, D.E. and C.O. Rutledge. Alteration of catecholamine uptake in cerebral cortex from rats fed a saturated fat diet. *Brain Res.* 179: 295-304, 1979.
11. Rutledge, C.O., D.E. Brenneman and L.C. Wince. Alteration of neuronal function associated with changes in a lipid environment of the neuronal membrane. Proc. Int'l. Workshop on Neuropharmacology. Taipei, 29-35, 1981.
12. Brenneman, D.E. and C.O. Rutledge. Effect of dietary lipid on locomotor activity and response to psychomotor stimulants. *Psychopharmacology* 76: 260-264, 1982.
13. Schrier, B.K., E.A. Neale, P.K. Sher, K.F. Swaiman, D.E. Brenneman, K.W. Cheng, W.H. Habig, W.H. Oertel and P.G. Nelson. GABA uptake and other cell markers distinguish cell types in drug toxicity studies with dispersed cultures of developing CNS cells. In *Problems in*

GABA research. From brain to bacteria. Y. Okada and E. Roberts, editors. Excerpta Medica, Amsterdam-Oxford-Princeton. 565: 268-279, 1982

14. Jackson, M.B., H. Lecar, D.E. Brenneman, S. Fitzgerald and P.G. Nelson. Electrical development in spinal cord cell culture. *J. Neurosci.* 2: 1052-1061, 1982.
15. P.G. Nelson and D.E. Brenneman. Electrical activity of neurons and development of the brain. *Trends in Neurosci.* 5: 229-232, 1982.
16. Brenneman, D.E., E. Neale, W. Habig and P.G. Nelson. Developmental and neurochemical specificity of neuronal death produced by electrical blockade in dissociated spinal cord cultures. *Dev. Brain Res.* 9: 13-27, 1983.
17. Handelmann, G.E., M.C. Beinfeld, T.L. O'Donohue, J.B. Nelson and D.E. Brenneman. Extra-hippocampal projections of CCK neurons of the hippocampus and subiculum. *Peptides* 4:331-334, 1983.
18. Brenneman, D.E. and D. Warren. Induction of cholinergic expression in developing spinal cord cultures. *J. Neurochem.* 41: 1349-1356, 1983.
19. Brenneman, D.E., S. Fitzgerald and P.G. Nelson. Interaction between trophic action and electrical activity in spinal cord cultures. *Dev. Brain Res.* 15:211-217, 1984.
20. Westbrook, G. and D.E. Brenneman. The development of spontaneous electrical activity in spinal cord cultures. In Caciagli, F. (ed.): *Physiological and Pharmacological Control of Nervous System Development*. Amsterdam, Elsvier Press, 1984, pp 11- 17.
21. Brenneman, D.E. and P.G. Nelson. Neuronal development in culture: role of electrical activity. In Bottenstein, J.E. and Sato, G (eds.): *Cell Culture in the Neurosciences*. New York, Plenum, 1985; pp 289-316.
22. Litzinger, M.J. and D.E. Brenneman. TTX displacement of <sup>3</sup>H-nitrendipine binding in developing spinal cord neurons. *Biochem. Biophys. Res. Comm.* 124: 979-987, 1985.
23. Litzinger, M.J. and D.E. Brenneman. The development of <sup>3</sup>H-nitrendipine binding in dissociated spinal cord cultures. *Biochem. Biophys. Res. Comm.* 127: 979-987, 1985.
24. Brenneman, D.E., S. Fitzgerald and M.J. Litzinger. Neuronal survival during electrical blockade is increased by 8-bromo cyclic adenosine 3',5' monophosphate. *J. Pharmacol. Exp. Therap.* 233: 402-408, 1985.
25. Brenneman, D.E., L.E. Eiden and R.E. Siegel. Neuropeptide regulation of neuronal development in spinal cord cultures. *Peptides* 6: 35-39, 1985.

26. Brenneman, D.E. and L.E. Eiden. Vasoactive intestinal peptide and electrical activity influence neuronal survival. *Proc. Natl. Acad. Sci. USA* 83: 1159-1162, 1986.
27. Litzinger, M.J., G.A. Foster and D.E. Brenneman. <sup>3</sup>H-Nitrendipine binding in non-neuronal cell cultures. *Biochem. Biophys. Res. Comm.* 136: 783-788, 1986.
28. Brenneman, D.E. Role of electrical activity and trophic factors during cholinergic development in dissociated cultures. *Can. J. Pharmacol. Physiol.* 64: 356-362, 1986.
29. Litzinger, M.J., A. Lombet, D.E. Brenneman and M. Lazdunski. <sup>3</sup>H-Tetrodotoxin binding in neuronal and non-neuronal spinal cord cultures. *Biochem. Biophys. Res. Comm.* 138: 1250-1256, 1986.
30. Brenneman, D.E. and P.G. Nelson. Peptide modulation of neuronal differentiation in culture. In A. Vernadakis (ed.): *Model Systems in Development and Aging of the Nervous System*. Boston, Martinus Nijhoff, 1986, pp. 257-276.
31. Guthrie, P.B., D.E. Brenneman and E.A. Neale. The mouse spinal cord in dissociated cell culture: separate culture of dorsal and ventral halves. *Brain Res.* 420: 313-323, 1987.
32. Brenneman, D.E., E.A. Neale, G.A. Foster, S.W. d'Autremont and G.L. Westbrook. Non-neuronal cells mediate neurotrophic action of VIP. *J. Cell Biol.* 104: 1603-1610, 1987.
33. Brenneman, D.E. and G.A. Foster. Structural specificity of peptides influencing neuronal survival during development. *Peptides* 8: 687-694, 1987.
34. Brenneman, D.E. Regulation of activity-linked neuronal survival by vasoactive intestinal peptide. *Annals of the New York Academy of Sciences*. 527: 595-597, 1988.
35. Eiden, L.E., R.E. Siegel, P. Giraud and D.E. Brenneman. Ontogeny of enkephalin- and VIP-containing neurons in dissociated cultures of mouse spinal cord. *Dev. Brain Res.* 44: 141-150, 1988.
36. Brenneman, D.E., G.L. Westbrook, S.P. Fitzgerald, D.L. Ennist, Elkins, K.L., Ruff, M.R. and C.B. Pert. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. *Nature* 335: 639-642, 1988.
37. Brenneman, D.E., J.M. Buzy, M.R. Ruff and C.B. Pert. Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus. *Drug Dev. Res.* 15: 361-369, 1988.
38. Buzy, J.M., D.E. Brenneman, Siegal, F.P., M.R. Ruff and C.B. Pert. Gp120-like neuronal killing in vitro by the cerebrospinal fluid from a demented AIDS patient *Am. J. Med.* 87: 361-362, 1989.

39. Foster, G.A., L.E. Eiden and Brenneman, D.E. Regulation of discrete sub-populations of transmitter-identified neurones after inhibition of electrical activity in cultures of mouse spinal cord. *Cell Tissue Res.* 256: 543-552, 1989.

40. Gozes, I., E. Meltzer, S. Rubinrout, D.E. Brenneman and Fridkin, M. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. *Endocrinol.* 125: 2945-2459, 1989.

41. Brenneman, D.E., I.D. Forsythe, T. Nicol and P.G. Nelson. N-methyl-D-aspartate receptors influence neuronal survival in developing spinal cord cultures. *Dev. Brain Res.* 51: 63-68, 1990.

42. Gozes, I. and D.E. Brenneman. VIP: molecular biology and neurobiological function. *Mol. Neurobiol.* 3: 201-236, 1990.

43. Brenneman, D.E. Peptide intervention of neuronal death caused by HIV external envelope protein: clinical implications. *Neuropsychopharmacol.* 3:722-730, 1990.

44. Brenneman, D.E., T. Nicol, D. Warren and L.M. Bowers. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. *J. Neurosci. Res.* 25: 386-394, 1990.

45. Brenneman, D.E., S.K. McCune and I. Gozes. Acquired immune deficiency syndrome and the developing nervous system. *Interntl. Review of Neurosci.* 32: 305-353, 1990.

46. Brenneman, D.E., C. Yu and P.G. Nelson. Multi-determinate regulation of neuronal survival: neuropeptides, excitatory amino acids and bioelectric activity. *Int. J. Devl. Neurosci.* 8: 371-378, 1990.

47. Kanterman, R.Y., C.C. Felder, D.E. Brenneman, A.L. Ma, S. Fitzgerald and J. Axelrod. Alpha-1-adrenergic receptor mediates arachidonic acid release in spinal cord neurons independent of inositol phospholipid turnover. *J. Neurochem.* 54: 1225-1232, 1990.

48. Markwell, M.A.K., H.Z. Sheng, D.E. Brenneman and S.M. Paul. A rapid method to quantify neurons in mixed cultures based on the specific binding of [<sup>3</sup>H]ouabain to neuronal Na<sup>+</sup>,K<sup>+</sup>-ATPase. *Brain Res.* 538: 1-8, 1991.

49. Foster, G.A., Eiden, L.E. and Brenneman, D.E. Enkephalin expression in spinal cord neurones is modulated by drugs related to classical and peptidergic transmitters. *Eur. J. Neurosci.* 3:32-39, 1991.

50. Gozes, Y., Brenneman, D.E., Fridkin, M., Asofsky, R. and Gozes, I. Novel VIP antagonist which distinguishes between VIP receptors on spinal cord cells and lymphocytes. *Brain Res.* 540: 319-321, 1991.

51. Hill, J.M., Gozes, I., Hill, J.L., Fridkin and Brenneman, D.E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. *Peptides* 12: 187-192, 1991.

52. Agoston, D.V., Eiden, L.E. and Brenneman, D.E. Calcium-dependent regulation of the enkephalin phenotype by neuronal activity during early ontogeny. *J. Neurosci. Res.* 28: 140-148, 1991.

53. Agoston, D.V., Eiden, L.E., Brenneman, D.E. and Gozes, I. Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cultures. *Mol. Brain Res.* 10:235-240, 1991.

54. Gozes, Y., McCune, Jacobson, L., Warren, D., Moody, T.W., Fridkin, M. and Brenneman, D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. *J. Pharmacol. Exp. Therap.* 257: 959-966, 1991.

55. Glowa, J.R., Panlilio, L.V., Brenneman, D.E., Gozes, I. and J.M. Hill. Learning impairment produced by the HIV envelope protein gp120. *Brain Res.* 570: 49-53, 1992.

56. Brenneman, D.E., Schultzberg, M., Bartfai, T. and Gozes, I. Cytokine regulation of neuronal survival. *J. Neurochem.* 58: 454-460, 1992.

57. Buzy, J., Brenneman, D.E., Pert, C.B., Martin, A., Salazar, A. and Ruff, M.R. Potent neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals. *Brain Res.* 598: 10-18, 1992.

58. Moody, T.W., Zia, F., Goldstein, A.L., Naylor, P.H., Sarin, E., Brenneman, D.E., Koros, A.M.C., Reubi, J.C., Korman, L.Y., Fridkin, M. and Gozes, I. VIP analogues inhibit small cell lung cancer growth. *Biomedical Res.* 13: suppl. 2, 131-135, 1992.

59. Gozes, I. and Brenneman, D.E. Vasoactive intestinal peptide: from molecular genetics to neurotropism. *Growth Factors, Peptides and Receptors*, T. W. Moody Ed., Plenum Press, New York, pp 15-20, 1993.

60. Gozes, I. and Brenneman, D.E. Neuropeptides as growth and differentiation factors in general and VIP in particular. *J. Molecular Neurosci.* 4: 1-10, 1993.

61. Nelson, P.G. and Brenneman, D.E. Neurotoxicology in vitro. In: *In vitro toxicology*, Gad, S.C., ed., New York: Raven Press, pp. 123-147, 1994.

62. Hill, J.M., Mervis, R.F., Avidor, R., Moody, T.W. and Brenneman, D.E. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. *Brain Res.* 603: 222-233, 1993.

63. Summers, R.W., Wu, X-R., Fitzgerald, Brenneman, D.E. and Agoston, D.V. Excitatory amino acid regulation of the enkephalin phenotype in mouse embryonic spinal cord cultures. *Dev. Brain Res.* 73: 185-192, 1993.

64. Gressens, P., Hill, J.M., Gozes, I., Fridkin, M. and Brenneman, D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. *Nature* 362: 155-158, 1993.

65. Moody, T.W., Zia, F., Draoui, M., Brenneman, D.E., Fridkin, M., Davidson, A. and Gozes, I. A novel VIP antagonist inhibits non-small cell lung cancer growth. *Proc. Natl. Acad. Sci. (USA)* 90: 4345-4349, 1993.

66. Brenneman, D.E., S.W. Page, M. Schultzberg, F.S. Thomas, P. Zelazowski, R. Avidor and E.M. Sternberg. A decomposition product of the contaminant implicated in L-tryptophan eosinophilia myalgia syndrome kills spinal cord neurons by stereospecific, interleukin-1 dependent mechanisms. *J. Pharmacol. Exp. Therap.* 266: 1029-1035, 1993.

67. Hill, J.M. and D.E. Brenneman. Vasoactive intestinal peptide and astrocyte mitogenesis: in vitro and in vivo studies. *Growth Factors, Peptides and Receptors*. Ed. by T.W. Moody, Plenum Press, New York, 1993, pp. 199-210.

68. Gozes, I., Glowa, J., Brenneman, D.E., McCune, S.K., Lee, E. and Westphal, H. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. *J. Molecular. Neurosci.* 4: 185-195, 1993.

69. Olah, Z., Lehel, C., Anderson, W.B., Brenneman , D.E. and Agoston, D.V. Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. *J. Neurosci. Res.* 39: 355-363, 1994.

70. Fatatis, A., Holtzclaw, L.A., Avidor, R., Brenneman, D.E. and Russell, J.T. VIP increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. *Proc. Natl. Acad. Sci. USA.* 91: 2036-2040, 1994.

71. Sone, M., Smith , D.M., Gozes, I., Brenneman, D.E., Fridkin, M., Ghatei, M.A. and Bloom, S.R. Pituitary adenylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) receptor subtypes in rat tissues: investigation of receptor binding and molecular identification by chemical cross linking. *Biomedical Research* 15: 145-153, 1994.

72. Hill, J.M., Mervis, R.F., Politi, J., McCune, S.K., Gozes, I., Fridkin, M. and Brenneman, D.E. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. *Annals of the New York Academy of Sciences* 739: 253-261, 1994.

73. Gozes, I., Brenneman, D.E., Lilling , G., Davidson, A. and Moody, T.W. Neuropeptide regulation of mitosis. *Annals of the New York Academy of Science* 739: 253-261, 1994.

74. Arimura, A., Somogyi-Vigh, A., Weill, C., Fiore, C., Tatsuno, I., Bay, V. and Brenneman, D. E. PACAP functions as a neurotrophic factor. *Annals of the New York Academy of Science* 739: 228-243, 1994.

75. Brenneman, D.E., McCune ,S., Mervis, R.F. and Hill, J.M. Gp120 as an etiologic agent for neuroAIDS: neurotoxicity and model systems. *Adv. Neuroimmunol.* 4:157-165, 1994.

76. Brenneman, D.E. Neurotrophism, mitogenesis and nerve regeneration as models for neuropeptide mediation. *Ann. N.Y. Acad. Sci.* 739: 226-227, 1994.

77. Gressens, P., Hill, J.M., Paindaveine, B., Gozes, I., Fridkin, M. and Brenneman, D.E. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. *J. Clin. Invest.* 94: 2020-2027, 1994.

78. Gozes, I., Fridkin, M., Westphal, H., Glowa, J., Hill, J.M., Bardea, A., Reshet, A., Zhukovsky, S., Waner, T., Niska, A., Rubinrout, S., Lilling, G., Davidson, A. Glazer-Steiner, R., Moody, T., Rostene, W. and Brenneman, D.E. Neuronal VIP: from gene to sexual behavior, memory and clinical application from Vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and related regulatory peptides from molecular biology to clinical applications. (ed. G. Rosselin). World Scientific, Singapore, 1994, pp 314-324.

79. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Asheknazi, I.E., Davidson, A., Rubinrout, S., Fridkin, M. and Brenneman, D.E. Superactive lipophilic peptides discriminate multiple VIP receptors. *J. Pharmacol. Exp. Therap.* 273: 161-167, 1995.

80. Brenneman, D.E., Hill, J.M., Glazner, G.W., Gozes, I., Phillips, T.M. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. *Intl. J. of Devol. Neurosci.* 13: 187-200, 1995.

81. Lilling, G., Wollman, Y., Goldstein, M.N., Rubinrout, S., Fridkin, M., Brenneman, D.E. and Gozes, I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. *J. Molecular Neurosci.* 5: 231-239, 1995.

82. Gozes, I., Fridkin, M. and Brenneman, D.E. Stearyl-Nle-VIP: a non-invasive impotence drug and a potent agent of neuroprotection. *Drugs of the Future.* 20(7): 680-695, 1995.

83. Gozes, I., Fridkin, M. and Brenneman, D.E. A VIP hybrid antagonist: from neurotrophism to clinical applications. *Cellular and Molecular Neurobiology.* 15: 675-687, 1995.

84. Lipton, S.A., Brenneman, D.E., Silverstein, F.S., Masliah, E. And Mucke, L. Gp120 and neurotoxicity in vivo. *Trends Pharmacol. Sci.* 16: 122, 1995.

85. Agoston, D.V., Palkovits, C.G., Fitzgerald, S.F. and Brenneman, D.E. Developmental changes in the inducibility of fos-like immunoreactivity in primary embryonic spinal cord cultures. *Dev. Brain Res.* 89: 173-186, 1995.

86. Hill, J.M., McCune S.K., Alvero, R.J., Glazner, G. and Brenneman, D.E. VIP regulation of embryonic growth. *Annals N.Y. Acad. Sci.* 805: 259-269, 1996.

87. Brenneman, D.E., Hill, J.M., Gozes, I. and Phillips, T.M. Vasoactive intestinal peptide releases interleukin-1 from astrocytes. *Annals N.Y. Acad. Sci.*, 805: 280-289, 1996.

88. Gozes, I., Bardea A., Reshef, A., Zamostiatno, R., Zhukovsky, S. Rubinraut, S., Fridkin, M. and Brenneman, D.E. Novel neuroprotective strategy for Alzheimer's disease: inhalation of a fatty neuropeptide. *Proc. Natl. Acad. Sci. USA* 93: 427-432, 1996.

89. Festoff, B.E., Nelson, P.G. and Brenneman, D.E. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting, neurotrophic serpin, protease nexin I. *J. Neurobiol.* 30: 255-266, 1996.

90. Hill, J.M., McCune, S.K., Alvero, R.J., Glazner, G., Henins, K., Stanziale, S.F., Keimowitz, J.R. and Brenneman, D.E. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. *J. Clin. Invest.* 97: 1-7, 1996.

91. Brenneman, D.E. and Gozes, I. A femtomolar acting neuroprotective peptide. *J. Clin. Invest.* 97: 2299-2307, 1996.

92. Gozes, I. and Brenneman, D.E. Activity-Dependent Neurotrophic Factor (ADNF): an extracellular neuroprotective chaperonin ? *J. Mol. Neurosci.* 7:235-244, 1996.

93. Gozes, I., Lilling, G., Davidson, A., Bardea A., Reshef, A., Glazer, R., Zamostiano, R./ Asjir-Fabian, O., Ticher, A., Ashkenazi, I.E., Moody, T.W., Rubinraut, S., Fridkin, M. and Brenneman, D.E. Development of VIP agonists and antagonists with tissue and receptor specificity: effects of behavioral maturation, sexual function and the biologic clock. *Annals New York Acad. Sci.*, 805: 159-171, 1996.

94. Glazner, G.W., Yadiv, K., Fitzgerald, S.F., Coven, E., Brenneman, D.E. and Nelson, P.G. Cholinergic stimulation increases thrombin activity and gene expression in cultured rat muscle. *Dev. Brain Res.* 99:148-154, 1997.

95. Brenneman, D.E., Hill, J.M., Gressens, P. and Gozes, I. Neurotrophic action of VIP: From CNS Ontogeny to Therapeutic Strategy. In *Pro-Inflammatory and Anti-inflammatory Peptides, Lung Biology in Health and Disease Series*, Sami Said, ed., Marcel Dekker Inc., New York. Volume 112, pp 383-402.

96. Hill, J.M., Gressens, P. and Brenneman, D.E. Growth of the early postimplantation embryo: regulation by high affinity, GTP-insensitive VIP receptors. *Annals New York Acad. Sci.* 814:174-180, 1997.

97. Gozes, I., Bardea, A., Bechar, M., Pearl, O., Reshef, A., Zamostiana, R., Davidson, A., Rubinraut, S., Giladi, E., Fridkin, M. and Brenneman, D.E. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's Disease. *Annals New York Acad. Sci.*, 814: 161-166, 1997.

98. Gressens, P., Paindaveine, B., Hill, J.M., Brenneman, D.E. and Evrard, P. Growth factor properties of VIP during early brain development. *Annals New York Acad. Sci.* 814: 152-160, 1997.

99. Brenneman, D.E., Phillips, T.M., Festoff, B.W. and Gozes, I. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. *Annals New York Acad. Sci.*, 814:167-173, 1997

100. Gozes, I., Davidson, A., Gozes, Y., Mascolo, R., Barth, R., Warren, D., Hauser, J., and Brenneman, D.E. Antiserum to activity dependent neurotrophic factor produces neuronal cell death in CNS cultures: Immunological and Biological Specificity. *Dev. Brain Res.* 99: 167-175, 1997.

101. Brenneman, D.E., Hill, J.M. and Gozes, I. Vasoactive intestinal peptide in the central nervous system. In *Psychopharmacology: 4th Generation of Progress*, Stanley Watson, ed., Lippincott-Raven, Philadelphia. CD-ROM Format.

102. Dibbern, D.A., Glazner, G.W., Gozes, I., Brenneman, D.E. and J.M. Hill. Inhibition of murine embryonic growth by HIV envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. *J. Clin. Invest.* 99: 2837-2841, 1997.

103. Gressens, P., Marret, S., Hill, J.M., Brenneman, D.E., Gozes, I., Fridkin, M. and Evrard, P. Vasoactive intestinal peptide prevents excitotoxic death in the murine developing brain. *J. Clin. Invest.* 100: 390-397, 1997.

104. Brenneman, D.E. The Synapse: Function, Plasticity and Neurotrophism. Review in *J. Chem. Neuroanatomy* 12: 221-222, 1997.

105. Wu, J.Y., Henins, K.A., Gressens, P., Gozes, I., Fridkin, M., Brenneman, D.E. and Hill, J.M. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. *Peptides*. 18: 1131-1137, 1997.

106. Ashur-Fabian, O., Giladi, E., Brenneman, D.E. and Gozes, I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. *J. Mol. Neubiol.* 9: 211-222, 1997.

107. Zupan, V., Hill, J.M., Brenneman, D.E., Gozes, I., Fridkin, M., Robberecht, P., Evrard, P. and Gressens, P. Involvement of PACAP II VIP2 receptor in mouse neocortical astrocytogenesis. *J. Neurochem.* 70: 2165-2173, 1998.

108. Gressens, P., Paindaveine, B., Hill, J.M., Evrard, P., and Brenneman, D.E.

Vasoactive intestinal peptide shortens both G1 and S phases of cell cycle in whole postimplantation cultured mouse embryos. *Europ. J. Neurosci.* 10: 1734-1742, 1998.

109. Koh, S.W., Yeh, T.H., Morris, S.M., Leffler, M., Higginbotham, E.J., Brenneman, D.E. and Yue, B.Y. Vasoactive intestinal peptide stimulation of human trabecular meshwork cell growth. *Invest. Ophthalmol. Vis. Sci.* 38: 2781-2789, 1997.

110. Brenneman, D.E., Hauser, J., Neale, E. A., Rubinraut, S., Fridkin, A., Davidson, A and Gozes, I. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. *J. Pharmacol. Exp. Therap.* 285:619-627, 1998.

111. Bassan, M., Zamostiano, R., Giladi, E., Davidson, A., Wollman, Y., Pitman, J., Hauser, J., Brenneman, D.E. and Gozes, I. The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. *Neurosci. Letters* 249:1-4, 1998.

112. Delgado, M., Munoz-Elias, J., Kan, Y., Gozes, I., Fridkin, J., Brenneman, D.E., Gomariz, R.P. And Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element -binding Protein/c-Jun. *J. Biol. Chem.* 273:31427-31436, 1998.

113. Brenneman, D.E., Glazner, G., Hill, J.M., Hauser, J., Davidson, A. and Gozes, I. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. *Ann. N.Y. Acad. Sci.* 865:207-212, 1998.

114. Bassan, M., Zamostiano, R., Davidson, A., Pinchasov, A., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G., Brenneman, D.E. and Gozes, I. The complete cDNA sequence of a femtomolar-acting activity-dependent neuroprotective protein. *J. Neurochem.* 72:1283-1293, 1999.

115. Glazner, G.W., Gressens, P., Lee, S.J., Gibney, G.M., Gozes, I., Gozes, Y., Brenneman, D.E. and Hill, J.M. Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. *Anat. Embryol.* 200: 65-71, 1999.

116. Zamostiano, R., Pinhasov, A., Bassan, M., Perl, M., Perl, O., Steingart, R.A. Atlas, R., Brenneman, D. and Gozes, I. A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. *Neurosci. Letts.* 264: 9-12, 1999.

117. Hill, J.M., S.J. Lee, Dibbern, D.A., Fridkin, M. Gozes, I. and Brenneman, D.E. Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localizaiton and role in embryonic growth. *Neurosci.* 93:783-791, 1999.

118. Spong, C.Y., Lee, S.J., McCune, S.K., Gibney, G., Abebe, D., Alvero, R., Brenneman, D.E. and Hill, J.M. Regulation of embryonic growth: the role of vasoactive intestinal peptide. *Endocrinology* 140:917-924, 1999.

119. Brenneman, D.E., Hauser, J., Spong, C.Y., Phillips, T.M., Pert, C.B. and Ruff, M. VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 gp120-induced neuronal death. *Brain Research* 838:27-36, 1999

120. Wang, H.Y., Jiang, X., Gozes, I., Fridkin, M., Brenneman, D.E. and Ganea, D. Vasoactive intestinal peptide inhibits cytokine production in T-lymphocytes through cAMP-dependent and c-AMP independent mechanisms. *Regulatory Peptides* 84: 55-67, 1999.

121. Glazner, G.W., Boland, F., Dresse, A.E., Brenneman, D.E., Gozes, I., Mattson, M.P. Activity-dependent neurotrophic peptide (ADNF-9) protects against oxidative stress-induced death. *J. Neurochem.* 73:2341-2347, 1999.

122. Brenneman, D.E., Hauser, J., Phillips, T.M., Davidson, A., Bassan, M. and Gozes, I. Link between electrical activity and glia-mediated neurotrophism. In *Neuropeptides: structure and function in biology and behavior*. Annals N.Y. Acad. Sci. 897:17-26, New York Acad. Sci, New York, 1999.

123. Hill, J.M., Glazner, G.W., Lee, S.J., Gozes, I., Gressens, P., Brenneman, D.E. Vasoactive intestinal peptide regulates embryonic growth through the action of activity dependent neurotrophic factor. In *Neuropeptides: structure and function in biology and behavior*. Annals N.Y. Acad. Sci. 897:92-100, New York Acad. Sci, New York, 1999.

124. Spong, C.Y., Lee, S.J., McCune, S.K., Gibney, G., Abebe, D.T., Brenneman, D.E. and Hill, J.M. Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide. In *Neuropeptides: structure and function in biology and behavior*. Annals N.Y. Acad. Sci. 897:101-108, New York Acad. Sci, New York, 1999.

125. Gozes, I., Bassan, M., Zamostiano, R., Pinhasov, A., Davidson, A., Giladi, E., Perl, O., Glazner, G.W. and Brenneman, D.E. A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. In *Neuropeptides: structure and function in biology and behavior*. Annals N.Y. Acad. Sci. 897:125-135, New York Acad. Sci, New York, 1999.

126. Offen, D., Sherki, Y., Melamed, E., Fridkin, M., Brenneman, D.E. and Gozes, I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. *Brain Res.* 854:257-262, 2000.

127. White, D.M., Walker, S., Brenneman, D.E. and Gozes, I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. *Brain Res.* 868: 31-38, 2000.

128. Gozes, I., Giladi, E., Pinhasov, A., Bardea, A. and Brenneman, D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. *J. Pharmacol. Exp. Ther.* 293:1091-1098, 2000.

129. Gozes, I. and Brenneman, D.E. A new concept in the pharmacology of neuroprotection. *J. Molecular Neurosci.* 14:61-68, 2000.

130. Paul, S., Kalaga, R.S., Gololobov, G. and Brenneman, D.E. Natural catalytic immunity is not restricted to autoantigenic substrates-Identification of a human immunodeficiency virus gp120-cleaving antibody light chain. *Applied Biochem. & Biotechnology* 83:71-82, 2000.

131. Blondel, O., Collin, C., McCarran, B., Zhu S., Zamonstiano, R., Gozes, I., Brenneman, D.E. and McKay, R..D.G. A glia-derived signal regulating neuronal differentiation. *J. Neurosci.* 20: 8012-8020, 2000.

132. Brenneman, D.E , Spong, C.Y. and Gozes, I. Protective peptides derived from novel glial proteins. *Biochem. Soc. Transactions.* 28, 452-455, 2000.

133. Zemlyak, S., Furman, S., Brenneman, D.E. and Gozes, I. A novel peptide NAP prevents death in enriched neuronal cultures. *Regulatory Peptides* 96:39-43, 2000.

134. Steingart, R.A., Solomon, B., Brenneman, D.E., Fridkin, M. and Gozes, I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. *J. Molecular Neurosci.* 15: 137-145, 2000.

135. Sigalov, E., Steingart, R.A., Fridkin, M., Brenneman, D.E. and Gozes, I. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells: A model for ischemic/hypoxic injury. *J. Molecular Neurosci.* 15: 147-154, 2000.

136. Brenneman, D.E., Hauser, J., Spong, C.Y., Phillips, T.M. Chemokines released from astroglia by vasoactive intestinal peptide: Mechanism of neuroprotection from HIV envelope protein toxicity. *Ann. N.Y. Acad. Sci.* 921: 109-114, 2000.

137. Gozes, I., Zamostiano, R., Pinhasov, A., Bassan, M., Giladi, E., Steingart, R.A. Brenneman, D.E. A novel VIP responsive gene- Activity dependent neuroprotective protein. *Ann. N.Y. Acad. Sci.* 921: 115-118, 2000.

138. Zamostinao, R., Pinhasov, A., Gelber, E., Steingart, R.A., Seroussi, E., Gilabi, E., Bassan , M., Wollman, Y., Eyre, H.J., Mulley, J.C., Brenneman, D.E. and Gozes, I. Cloning and characerization of the human activity-dependent neuroprotective protein. *J. Biol. Chem.* 276: 708-714, 2001.

139. Beni-Adani, L., Gozes, I., Cohen, Y., Assaf, Y., Brenneman, D.E., Eizenberg, O., Trembolver, V. and Shohami, E. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. *J. Pharmacol. Exp. Therap.* 296:57-63, 2001.

140. Spong, C.Y., Abebe, D., Gozes, I., Brenneman, D.E. and Hill, J.M. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. *J. Pharmacol. Exp. Therp.* 297:774-779, 2001.

141. Moody, T.W., Leyton, J., Chan, D., Brenneman, D.E., Fridkin, M., Gelber, E., Levy, A. and Gozes, I. VIP receptor antagonist and chemotherapeutic drugs inhibit the growth of breast cancer cells. *Breast Cancer Res and Treatment* 1911: 1-10, 2001.

142. Servoss, S.J., Lee, S.J., Gibney, G., Gozes, I., Brenneman, D.E. and Hill, J.M. Insulin-like growth factor as a mediator of vasoactive intestinal peptide/activity dependent neurotrophic factor-simulated embryonic growth. *Endocrinology* 142: 3348-3353, 2001.

143. Ashur-Fabian, O., Giladi, E., Furman, S., Steingart, R.A., Wollman, Y., Fridkin, M., Brenneman, D.E. and Gozes, I. Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. *Neurosci. Letters* 307: 167-170, 2001.

144. Porter, A.E., Auth, J. Prince, M., Ghidini, A., Brenneman, D.E., Spong, C.Y. Optimization of cytokine stability in stored amniotic fluid. *Am J Obstet Gynecol* 2001:185:459-62, 2001.

145. Gelber, E., Granoth, R., Fridkin, M>, Dreznik, Z., Brenneman, D.E., Moody, T.W., Gozes, I. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. *Cancer*: 92:2172-2180, 2001.

## ABSTRACTS

1. Brenneman, D.E., W.E. Connor, E.L. Forker and L. DenBesten. Diet-induced cholesterol gallstones in prairie dogs. *J. Lab. Clin. Med.* 76: 1006, 1970.
2. Spector, A.A. and D.E. Brenneman. Fatty acid saturation affects microsomal cholesteryl ester synthetase activity. *Circulation (Supple. II)* 54: 7751, 1976.
3. Brenneman, D.E. and C.O. Rutledge. Alteration in norepinephrine uptake kinetics by a saturated fat diet in neonatal animals. *Fed. Proc.* 37: 751, 1978.
4. Brenneman, D.E. and C.O. Rutledge. Effect of dietary lipid composition on locomotor activity and psychomotor stimulant response. *Soc. for Neurosci. Abstr.* 5: 643, 1979.
5. Brenneman, D.E. and C.O. Rutledge. Beta receptor sub-sensitivity in neonatal cerebral cortex of rats fed a saturated fat diet. *Fed. Proc.* 39: 1006, 1980.
6. Brenneman, D.E., C.O. Rutledge, W.R. Hedrick, A.E. Mathew and J.D. Zimbrick. The effect of dietary lipid composition on membrane fluidity in rat cerebral cortex. *Fed. Proc.* 39, 2098, 1980.
7. Brenneman, D.E. and C.O. Rutledge. Fatty acyl composition of brain phospholipids in response to dietary lipid. *Trans. of Am. Soc. for Neurochem.* 12: 241, 1981.
8. Rutledge, C.O., D.E. Brenneman and L.C. Wince. Alteration of pre- and postsynaptic function by dietary lipid. *Eight International Congress of Pharmacology.* 1981.
9. Brenneman, D.E. Fatty acid-induced alteration in action potentials from dissociated spinal cord neurons. *Soc. for Neurosci. Abstr.* 7: 911, 1981.
10. Brenneman, D.E., E.A. Neale, L. Bowers and P.G. Nelson. Suppression of electrical activity is associated with neuronal deficits: developmental onset and neurochemical specificity. *Soc. for Neurosci. Abstr.* 8: 670, 1982.

11. Guthrie, P. and D.E. Brenneman. Mouse spinal cord in dissociated cell culture-separate culture of dorsal and ventral halves. *Soc. for Neurosci. Abstr.* 8: 233, 1982.
12. Rutledge, C.O., D.E. Brenneman, L.C. Wince, C.-F. Chiang, and D.D. Schoepp. Relationship of drug response to the lipid environment of the receptor. *Pharmacologist* 25: 106, 1983.
13. Westbrook, G.L., D.E. Brenneman, J. Baumgold and M.J. Litzinger. The development of spontaneous activity and <sup>3</sup>H-saxitoxin binding correlates with impulse-dependent neuronal survival. *Soc. for Neurosci. Abstr.* 9: 505, 1983.
14. Brenneman, D.E., S.P. Fitzgerald and P.G. Nelson. Conditioned media and cyclic AMP influence neuronal survival during electrical blockade. *Soc. for Neurosci. Abstr.* 9: 846, 1983.
15. Litzinger, M.J. and D.E. Brenneman. Developmental <sup>3</sup>H-nitrendipine binding in immature spinal cord neurons with incidental TTX displacement. *Pediatric Res.* 18: 155, 1984.
16. Litzinger, M.J. and D.E. Brenneman. TTX displacement of <sup>3</sup>H-nitrendipine binding in developing spinal cord neurons. *Soc. for Neurosci. Abstr.* 10: 526, 1984.
17. Brenneman, D.E., L.E. Eiden and R.E. Siegel. Vasoactive intestinal peptide increases activity-dependent neuronal survival in developing spinal cord cultures. *Soc. for Neurosci. Abstr.* 10: 1050, 1984.
18. Litzinger, M.J. and D.E. Brenneman. <sup>3</sup>H-Nitrendipine binding in non-neuronal cells from mouse spinal cord cultures. *Soc. for Neurosci. Abstr.* 11: 86, 1985.
19. Brenneman, D.E. Non-neuronal cells mediate VIP stimulation of neuronal survival during development in dissociated cultures. *Soc. for Neurosci. Abstr.* 11: 1148, 1985.
20. Brenneman, D.E. Role of electrical activity and trophic factors during cholinergic development of dissociated cultures. *Proc. Can. Fed. of Biol. Soc.* 28: 10, 1985.
21. Wang, F.Z., D.E. Brenneman and P.G. Nelson. Cholinergic function and vasoactive intestinal polypeptide in mouse spinal cord cell cultures. *Proc. Congress International Union of Physiol. Sci.* 1986.
22. Brenneman, D.E. and P.G. Nelson. Neuronal activity-dependent modulation of nervous system development. *International Soc. for Dev. Neurosci.* 4: (suppl. 1) 40, 1986.
23. Alderson, R.F. and D.E. Brenneman. Regulation of choline acetyltransferase activity by protein kinase C in dissociated mouse spinal cord-dorsal root ganglion cultures. *Soc. for Neurosci. Abstr.* 12: 321, 1986.

24. Brenneman, D.E. Comparison of vasoactive intestinal peptide, VIP (10-28), PHI-27, secretin and GRF for effects on neuronal survival in developing spinal cord cultures. Soc. for Neurosci. Abstr. 12: 870, 1986.
25. Brenneman, D.E., T. Nicol. and L. Bowers. Neuropeptide regulation of astroglial proliferation. Fed. Proc. 46: 1450, 1987.
26. Foster, G.A. and D.E. Brenneman. Differential sensitivity of transmitter-identified neurons to the lethal effects of inhibition of electrical activity in dissociated cultures of mouse spinal cord and DRG. Soc. for Neurosci. Abstr. 13: 9, 1987.
27. Alderson, R.F., D.A. Kniss and D.E. Brenneman. Vasoactive intestinal peptide-induced phosphorylation in primary cultures of cortical astrocytes. Soc. for Neurosci. Abstr. 13: 562, 1987.
28. Nelson, P.G., D.E. Brenneman, I. Forsythe, T. Nicol and G. Westbrook. NMDA antagonists increase neuronal death without blocking electrical activity in developing cultures. Soc. Neurosci. Abstr. 13: 9, 1987.
29. Brenneman, D.E., C. Pert and G. Westbrook. External envelope protein (gp120) of HIV produces neuronal death in hippocampal cultures. Soc. for Neurosci. Abstr. 13: 492, 1987.
30. Eiden, L.E., J.A. Waschek, D.E. Brenneman, R. Fischer-Colbrie and R.M. Pruss. Coordinate regulation of enkephalin secretion and biosynthesis. Trans. of Am. Soc. for Neurochem., 1988.
31. Pert, C.B., M.R. Ruff, J.M. Hill, D.E. Brenneman and E.M. Sternberg. AIDS as a neuropeptide disorder: Peptide T, VIP and the HIV receptor. IV International Con. on AIDS Abstr., 1988.
32. Brenneman, D.E., I. Forsythe and P.G. Nelson. NMDA receptors influence neuronal survival during a critical period of development in cell culture. International Soc. for Dev. Neurosci., 1988.
33. Brenneman, D.E. Two mechanisms contribute to the neuronal survival-promoting action of VIP: Neurotrophic factor releasing activity and glial mitosis. Soc. for Neurosci. Abstr. 14: 254, 1988.
34. Nelson, P.G., Yu, C., Fields, R.D. and Brenneman, D.E. NMDA receptor and calcium involvement in synapse elimination. Soc. for Neurosci. Abstr. 15: 127, 1989.
35. Brenneman, D.E., Schultzberg, M. and I. Gozes. Interleukin-1 antisera decreases neuronal survival in developing spinal cord cultures. Soc. for Neurosci. Abstr. 15: 381, 1989.

36. Pert, C.B., Mervis, R.F., Hill, J.M., Brenneman, D.E., Ruff, M.R., Switzer, R.C., Warren, B. and Glowka, J. Morphological and behavioral response to acute and subacute I.C.V. Gp120 administration in the rat. Soc. for Neurosci. Abstr. 15: 1387, 1989.

37. McCune, S.K., Brenneman, D.E. and Voigt, M.M. Developmental characterization and tissue distribution of a rat alpha-2 adrenergic receptor subtype. Soc. for Neurosci. Abstr. 15: 433, 1989.

38. Agoston, D.V., Gozes, I., Eiden, L.E. and Brenneman, D.E. Developmental regulation of vasoactive intestinal peptide-VIP mRNA in developing spinal cord. Soc. for Neurosci. Abstr. 15: 1271, 1989.

39. Gozes, I., Fridkin, M. and Brenneman, D.E. A novel antagonist to vasoactive intestinal peptide. Soc. for Neurosci. Abstr. 15: 216, 1989.

40. Brenneman, D.E. Glial proteins released by VIP: neurodevelopmental significance. Reg. Peptides 26: 146, 1989.

41. L.E. Eiden, Agoston, D.V., Brenneman D.E., Eskay, R.L. Rausch, D.M. and Waschek, J.A. First, second and third messenger control of VIP/PHI gene activity in neuroendocrine cells. Reg. Peptides 26: 153, 1989.

42. Gozes, I., Meltzer, E., Rubinrout, S., Fridkin, M. and Brenneman, D.E. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Reg. Peptides 26: 159, 1989.

43. Fatatis, A., Brenneman, D.E., Taglialatela, M., Canzoniero, L.M.T., Amoroso, S., di Renzo, G.F. and Annunziato, L. Na/Ca exchange activity in astrocytes in culture. Proc. Intl. Cong Neubiol.

44. Festoff, B.W., J.S. Rao and D.E. Brenneman. Vasoactive intestinal polypeptide (VIP) is a secretagogue for protease nexin I (PNI) release from astrocytes. Soc. for Neurosci. Abstrs. 16: 909, 1990.

45. Hill, J.M. and Brenneman, D.E. Gp120-induced retardation of behavioral development in neonatal rats: prevention by peptide T. Soc. for Neurosci. Abstrs. 16, 615, 1990.

46. Agoston, D.V., Wu, X.-R., Eiden, L.E. and Brenneman, D.E. NMDA and calcium regulate the enkephalinergic phenotype in developing spinal cord cultures. Soc. for Neursci. Abstrs. 16, 647, 1990.

47. Russel, J.T., A. Fatatis, P.G. Nelson and D.E. Brenneman. Vasoactive intestinal polypeptide (VIP) causes intracellular calcium oscillations in astrocytes. Soc. for Neurosci. Abstrs. 16, 994, 1990.

48. Gozes, Y., D.E. Brenneman, M. Fridkin, R. Assofsky and I. Gozes. VIP antagonist distinguishes between VIP receptors. *Trans. Am. Soc for Neurochem.* 21: 170, 1990.

49. Panlilio, L.V., Hill, J.M., Brenneman, D.E., Fridkin, M., Gozes, I. and Glowa, J.R. Gp120 and a vip receptor antagonist impair Morris water maze performance in rats. *Soc. for Neurosci. Abstrs.* 16, 1330, 1990.

50. Schwartz, J.P., Brenneman, D.E., Dubois-Dalcq, M., McMorris, F.A., Griffin, W.S.T. Glia: synthesis of and responses to growth factors and neuropeptides. *Soc. for Neurosci. Abstrs.* 16: 1269, 1990.

51. Mervis, R., Hill, J.M. and Brenneman, D.E. Prevention of gp120-induced neuronal damage in the developing rat by peptide T: a Golgi study. *Sixth International Conf. on AIDS.* 1: 184, 1990.

52. Hill, J.M. and Brenneman, D.E. Gp120-induced retardation of behavioral development in neonatal rats: prevention by peptide T. *Sixth International Conf. on AIDS* 2: 330, 1990.

53. Gozes, I., Hill, J.M., Mervis, R.F., Fridkin, M. and Brenneman, D.E. VIP antagonist produces neuronal damage and retardation of behavioral development in neonatal rats. *Soc. for Neurosci. Abstrs.* 16: 1292, 1990.

54. Brenneman, D.E. Two-dimensional electrophoretic analysis of glial proteins released by VIP. *Soc. for Neurosci. Abstrs.* 16, 820, 1990.

55. Summers, R.W., Brenneman, D.E., Fitzgerald, S.F. and Agoston, D.V. NMDA regulates the expression of the enkephalin phenotype in developing spinal cord cultures. *Soc. for Neurosci. Abstrs.* 17: 750, 1991.

56. Festoff, B.W. and Brenneman, D.E. Protease nexin I (PNI) increases the survival of spinal cord neurons. *Soc. for Neurosci. Abstrs.* 17: 754, 1991.

57. Sternberg, E.M., Page, S.W., Smith, M. and Brenneman, D.E. The (1S,3S)-isomer of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid, a breakdown product of peak 97 implicated in the L-tryptophan eosinophilia myalgia syndrome (L-TRP-EMS) stereospecifically prevents neuronal death in spinal cord cultures. *Soc. for Neurosci. Abstrs.* 17: 756, 1991.

58. Olah, Z., Komoly, S., Warren, D., Brenneman, D.E. and Agoston, D.V. Protein kinase C-related signal transduction pathway is triggered by subnanomolar concentration of VIP in astrocytes. *Soc. for Neurosci. Abstrs.* 17: 603, 1991.

59. Brenneman, D.E., Barth, R., Warren, D., Davidson, A. and Gozes, I. Purification of activity dependent neurotrophic factor (ADNF). *Soc. for Neurosci. Abstrs.* 17: 754, 1991

60. Hill., J.M., McCune, S.K., Gozes, I., Fridkin, M., Agoston, D. and Brenneman, D.E. VIP and VIP receptors during development in the rat brain: effects of treatment with a VIP antagonist. *Biomedical Res.* 12 (Suppl. 1): 9, 1991.
61. Moody, T., Zia, F., Brenneman, D.E., Fridkin, M. and Gozes, I. VIP analogues inhibit non-small cell lung cancer growth. *Biomedical Res.* 12 (Suppl. 1): 11, 1991.
62. Fatatis, A., Brenneman, D.E. and Russell, J. VIP mobilizes intracellular calcium in cultured astroglia. *Biomedical Res.* 12 (Suppl. 1) 32, 1991.
63. Brenneman, D.E. R. Avidor, R. Mascolo, Y. Gozes, A. Davidson and I. Gozes. Activity-dependent neurotrophic factor increases neuronal survival in cerebral cortical cultures *Neurology*, 42 (suppl 3) 169 (1992).
64. Gozes, I. and Brenneman, D.E. Electrical activity and neuropeptide gene expression in vivo and development of molecular probes for peptide blockade. Ninth International meeting of the International Society for Developmental Neuroscience. Suppl. (1) 10: 44, 1992.
65. Brenneman, D.E. and Gozes, I. Vasoactive intestinal peptide: a secretagogue for permissive glia-derived growth factors. *Internatl. Soc. for Dev. Neurosci.* Suppl. (1) 10:44, 1992.
66. Sternberg, E.M., S.W. Page, M. Schultzberg, F.S. Thomas, P. Zelazowski, R. Avidor and D.E. Brenneman. A decomposition product of the contaminant implicated in L-tryptophan eosinophilia myalgia syndrome kills spinal cord neurons by stereospecific, interleukin-1 dependent mechanisms. *Soc. Neurosci. Abstrs.* 18: 45, 1992.
67. Olah, Z., Cs. Lehel, D.E. Brenneman, A. Buonanno, W.B. Anderson, and D.V. Agoston. VIP and forskolin induces nuclear translocation of PKC isoenzymes in rat cortical astrocytes. *Soc. Neurosci. Abstrs.* 18: 65, 1992.
68. Davidson, A., E. Dicicco-Bloom, I. Black, M. Draoui, G. Liling, M. Fridkin, D.E. Brenneman, T.W. Moody and I. Gozes. The neuropeptide VIP: an autocrine regulator of cell growth. *Soc. Neurosci. Abstrs.* 18: 418, 1992.
69. Palkovits, C.G., D.E. Brenneman, S.C. Fitzgerald, R.W. Summers and D.V. Agoston. Developmental regulation of c-fos and its responsiveness in spinal cord cultures. *Soc. Neurosci. Abstrs.* 18: 623, 1992.
70. Lipton, S.A., C.A. Wiley, D.E. Brenneman, L. Pulliam, M. Heyes. Mechanisms of HIV-related injury in the central nervous system. *Soc. Neurosci. Abstrs.* 18: 914, 1992.
71. Gozes, I. Y. Gozes, R. Avidor, A. Davidson, D.E. Brenneman. Neutralizing antiserum to activity-dependent neurotrophic factor produces neuronal cell death in mammalian CNS cultures. *Soc. Neurosci. Abstrs.* 18: 1293, 1992.

72. Brenneman, D.E., H. Jaffe, T. Moody, J.M. Hill. Fragments of the envelope protein (gp120) from the human immunodeficiency virus are neurotoxic to CNS cultures. *Soc. Neurosci. Absts.* 18: 1592, 1992.

73. Gozes, I., R. Glazer, W. Rostene, B.S. McEwen and D.E. Brenneman. Expression and hormonal regulation of the VIP gene. *J. Endocrinol. Invest.* 16 (Supple. 1 to 8): 28, 1993.

74. Brenneman, D.E., P. Gressens, I. Gozes, M. Fridkin and J.M. Hill. Serum neuropeptide levels in pregnant rats: implications for regulation of embryonic growth and development. *J. Endocrinol. Invest.* 16 (Suppl. 1 to 8): 63, 1993.

75. Gozes, I., J. Glowa, D.E. Brenneman, S.K. McCune, E. Lee and H. Westphal. VIP function assessed by molecular genetic techniques. *J. Neurochem.* 61 (Suppl.): S86, 1993.

76. Gozes, I., M. Fridkin, H. Westphal, J. Glowa, A. Reshef, S. Zhukovsky, T. Waner, A. Niska, S. Rubinrout, G. Lilling, W. Rostene and D.E. Brenneman. Neuronal VIP: from gene to sexual behavior, memory and clinical applications. *Internat'l Sym. VIP, PACAP and Related Peptides* 1: 64, 1993

77. Gozes, I., A. Davidson, Y. Wollman, G. Lilling, M.N. Goldstein, M. Fridkin, D.E. Brenneman and T.W. Moody. Vasoactive intestinal peptide: an autocrine growth promotor in cancer cells. *Internat'l Sym. VIP, PACAP and Related Peptides* 1: 63, 1993.

78. Brenneman, D.E., P. Gressens, R. Avidor, J.M. Hill, B.W. Festoff, M. Schultzberg, A. Davidson and I. Gozes. Identification of multiple determinants of VIP neurotrophism for CNS neurons. *Internat'l Sym. VIP, PACAP and Related Peptides* 1: 33, 1993.

79. Gressens, P., B. Paindaveine, I. Gozes, M. Fridkin and D.E. Brenneman. Blockade of VIP functions in early mouse embryo induces severe microcephaly. *Internat'l Sym. VIP, PACAP and Related Peptides* 1: 66, 1993

80. Hill, J.M., T.W. Moody, S. K. McCune, P. Gressens and D.E. Brenneman. VIP and PACAP in the developing CNS: mRNA, receptors and maternal fetal interactions. *Internat'l Sym. VIP, PACAP and Related Peptides* 1: 71, 1993.

81. Brenneman, D.E., R. Avidor and I. Gozes. Interleukin-1 and vasoactive intestinal peptide: partners in CNS neurotrophism. *J. Neurochem.* 61 (Suppl.): S188, 1993.

82. Wollman Y., G. Lilling, M.N. Goldstein, M. Fridkin, D.E. Brenneman and I. Gozes. Vasoactive intestinal peptide: a growth promotor in neuroblastoma cells. *Soc. Neurosci. Absts.* 19: 1728, 1993.

83. Gozes, I., G. Lilling, A. Davidson, M. Fridkin and D.E. Brenneman. A ten-fold more potent VIP agonist that differentiates two CNS VIP receptors. *Soc. Neurosci. Absts.* 19: 1365, 1993.

84. Hill, J.M., S.K. McCune, J. Keimowitz and D.E. Brenneman. Indications that maternal VIP regulates prenatal growth and development. *Soc. Neurosci. Absts.* 19: 1102, 1993.

85. Glazner, R., A. Ticher, I.E. Ashkenazi, M. Fridkin, D.E. Brenneman and I. Gozes. VIP gene expression is involved in the determination of biological rhythms. *Soc. Neurosci. Absts.* 19: 572, 1993.

86. Brenneman, D.E. and I. Gozes. Prevention of gp120-associated neuronal cell death by activity-dependent neurotrophic factor. *Soc. Neurosci. Absts.* 19: 659, 1993.

87. Hill, J.M., Gressens, P., Paindaveine, B., Wu, J.Y., Gozes, I., Fridkin, M., and Brenneman, D.E. Microcephaly and delay of developmental behaviors induced by prenatal blockade of VIP. *Soc. Neurosci. Absts.* 20: 1096, 1994.

88. Gozes, I., Bardea, A., Reshef, A., Zamostiana, R., Zhukovsky, S., Rubinraut, S., Fridkin, M. and Brenneman, D.E. Lipophilic VIP analogues: novel drugs for treatment of neurodegenerative diseases. *Soc. Neurosci. Absts.* 21: 1778, 1994.

89. Lilling, G., Wollman, Y., Goldstein, M.N., Brenneman, D.E., Fridkin, M. Gozes, I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. *Soc. Neurosci. Absts.* 20: 1690, 1994.

90. Davidson, A., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I.E., Rubinraut, S., Fridkin, M., Brenneman, D.E. and Gozes, I. One hundred-fold more potent VIP agonist and antagonist. *Soc. Neurosci. Absts.* 20: 1351, 1994.

91. Glazner, G.W., Jain, N., Brenneman, D.E. and Hill, J.M. Differential gene expression of trophic factors between embryo and extraembryonic membranes in cultured E9 mice. *Soc. Neurosci. Absts.* 20: 1305, 1994.

92. Wu., J.Y., Moody, T.W., Brenneman , D.E. and Hill, J.M. Fetal brain accumulates gp120 systemically administered to pregnant mice. *Soc. Neurosci. Absts.* 20: 1258, 1994.

93. McCune, S.K., Coon, S.L., Brenneman, D.E. and Klein, D.C. Pineal alpha-1b adrenergic receptor mRNA: high abundance, development and adrenergic regulation. *Soc. Neurosci. Absts.* 20: 1067, 1994.

94. Brenneman, D.E., Hill, J.M., Gozes, I., and Phillips, T.M. Vasoactive intestinal peptide increases the secretion of eight cytokines from cerebral cortical astrocytes. *Soc. Neurosci. Absts.* 20: 695, 1994.

95. Agoston, D.V., Santha, E., Brenneman, D.E., Matsumoto, K. and Dobi, A.L. Gene structure and the molecular establishment of the neuronal phenotype. *J. Neurochem.* 63 (suppl 1) S18, 1994.

96. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, A., Davidson, A., Rubinraut, S., Fridkin, M. and Brenneman, D.E. Pharmacological discrimination of multiple VIP receptors with superactive lipophilic peptides. *J. Neurochem.* 63 (suppl. 1): S10, 1994.

97. Gressens, P., Hill, J.M., Gozes, I., Fridkin, M. and Brenneman, D.E. Prenatal administration of a VIP antagonist produces severe microcephaly. *J. Neurochem.* 63 (suppl. 1): S10, 1994.

98. Nelson, P.G., Yadav, K., Fitzgerald, S. and Brenneman, D.E. Activation of mouse skeletal muscle in vitro produces increased secretion of thrombin. *Soc. Neurosci. Absts.* 20: 1089, 1994.

99. Glazner, G.W., Wu, J.Y., Gressens, P., Gozes, I., Brenneman, D.E. and Hill, J.M. Vasoactive intestinal peptide stimulation of embryonic growth in cultured E9 mice is partially mediated through activity-dependent neurotrophic factor. *Soc. Neurosci. Absts.* 21: 1545, 1995.

100. Gressens, P., Paindaveine, B., Hill, J.M., Evard, P. and Brenneman, D.E. Vasoactive intestinal peptide-induced shortening of S phase in whole cultured mouse embryos. *Soc. Neurosci. Absts.* 21: 1546, 1995.

101. Brenneman, D.E., Hill, J.M., Gozes, I., Fridkin, M. and Phillips, T.M. Pharmacology of VIP-mediated release of cytokines from astroglial cultures. *Soc. Neurosci. Absts.* 21: 1599, 1995.

102. Gozes, I., Bachar, M., Bardea, A., Reshef, A., Rubinrout, S., Fridkin, M. and Brenneman, D.E. Stearyl-NLE17-VIP protects against developmental retardation in Apo E-deficient mice and against neurodegeneration in Alzheimer's disease-related models. *Soc. Neurosci. Absts.* 21: 1713, 1995.

103. Hill, J.M., Dibbern, D.A., Gozes, I., Fridkin, M., Brenneman, D.E. VIP analogue stimulates embryonic growth through GTP-insensitive binding sites. *Soc. Neurosci. Absts.* 21: 1783, 1995

104. Brenneman, D.E. and Gozes, I. A femtomolar-acting neuroprotective peptide derived from activity dependent neurotrophic factor. *Soc. Neurosci. Absts.* 22:743, 1996.

105. Hill, J.M., Gressens, P., Glazner, G. and Brenneman, D.E. Floor plate neuroepithelium has binding sites for growth regulator, vasoactive intestinal peptide. *Soc. Neurosci. Absts.* 22:1478, 1996.

106. Lee, S.J., Servoss, S.J., Cavanagh, A.C., Alewood, P.F., Morton, H., Brenneman, D.E. and Hill, J.M. Early pregnancy factor regulates brain growth of the early postimplantation (E9) mouse embryo. *Soc. Neurosci. Absts.* 22:743, 1996.

107. Servoss, S.J., Glazner, G.W., Lee, S.J., Gibney, G. Mechanism of vasoactive intestinal peptide-stimulated embryonic growth. *Soc. Neurosci. Absts.* 22:550, 1996.

108. Gozes, I., Davidson, A., Bardea, A., Bechar, M., Giladi, E. and Brenneman, D.E.

A 14-amino acid peptide protects against Alzheimer's-associated neurotoxicity in vivo.  
Soc. Neurosci. Absts. 22:743, 1996.

109. Davidson, A., Gozes, Y., Hauser, J., Brenneman, D.E. and Gozes, I. Identification of an active site for activity dependent neurotrophic factor. Soc. Neurosci. Absts. 22:744, 1996.

110. Gressens, P., Marret, S., Hill, J.M., Brenneman, D.E., Gozes, I., Fridkin, M. and Evrard, P. Vasoactive intestinal peptide prevents excitotoxic cell death in the developing brain. Soc. Neurosci. Absts. 22: 1965, 1996.

111. Basan, M., Zamostiano, R., Pitman, J., Hauser, J., Brenneman, D.E. and Gozes, I. The identification of secreted heat shock protein 60 (hsp60) from glial cells and neuroblasoma cell line. Israel Soc. for Neurosci. 32: S11, 1996.

112. Lee, S.J., McCune, S.K., Spong, C.Y., Gibney, G., Brenneman, D.E. and Hill, J.M. Localization of early pregnancy factor mRNA in mouse brain and embryo and efficacy of an active peptide in vivo and in vitro. Soc. Neurosci. Absts. 23:50, 1997.

113. Hauser, J., Ruff, M., Brenneman, D.E. and Pert, C. Chemokines prevent neuronal cell death associated with the HIV envelope protein (gp120). Soc. Neurosci. Absts. 23:993, 1997.

114. G. Gibney, Castellon, R., Glazner, G., Gozes, I. and Brenneman, D.E. Neutralizing antiserum to rat activity-dependent neurotrophic factor (ADNF I) detects a human homologue. Soc. Neurosci. Abst. 23:2250, 1997.

115. Brenneman, D.E., Neale, E.A., Williamson, L.C., Fridkin, M., Rubinraut, S., Davidson, A. and Gozes, I. Identification of a nine amino acid core peptide from activity dependent neurotrophic factor I. Soc. Neurosci. Absts. 23:2250, 1997.

116. Spong, C.Y., Lee, S.J., McCune, S.K., Gibney, G., Castellon, R., Brenneman, D.E. and Hill, J.M. Vasoactive intestinal peptide in the mouse embryo: mRNA, peptide immunoreactivity and binding sites in embryo and extraembryonic membranes. Soc. Neurosci. Absts. 23:50, 1997.

117. Hill, J.M., Chang, S., Glowa, J.R., Gressens, P., Abebe, D.T., Libel, C., Dibbern, D., Lee, S.J., Gibney, G., Gozes, I., Glazner, G. and Brenneman, D.E. Learning impairment in adult mice produced by early embryonic administration of antiserum to activity dependent neurotrophic factor (ADNF). Soc. Neurosci. Absts. 23:2250, 1997.

118. Davidson, A., Giladi, E., Bachar, M., Bardea, A., Rubinraut, S., Fridkin, M., Brenneman, D.E. and Gozes, I. Protection against developmental retardation and learning impairments in apolipoprotein E-deficient mice by activity-dependent, femtomolar-acting peptides. Soc. Neurosci. Absts. 23:2250, 1997.

119. Gozes, I., Bassan, M., Zamostiano, R., Davidson, A., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G. and Brenneman, D.E. The cDNA structure of a novel femtomolar-

acting neuroprotective protein: activity-dependent-neurotrophic factor III (ADNF III). *Soc. Neurosci. Absts.* 23:2250, 1997.

120. Basan, M., Zamostiano, R., Davidon, A., Perl, O., Bassan, H., Blat, C., Giladi, E., Gibney, G., Glazner, G., Brenneman, D.E. and Gozes, I. VIP-induced mechanism of neuroprotection: the complete sequence of a femtomolar-acting activity-dependent neuroprotective protein. *Reg. Peptides* 71: 105, 1997.
121. Brenneman, D.E., Glazner, G., Hill, J.M., Hauser, J., Davidson, A. and Gozes, I. VIP neuroprotection in the central nervous system: multiple effectors and identification of a femtomolar-activng neuroprotective peptide. *Reg. Peptides* 71: 107, 1997.
122. Hill, J.M., Glazner, G., Dibbern, D.A., Gozes, I., Gozes, Y., Gressens, P., Brenneman, D.E. VIP-stimulated release of activity-dependent neutrophic factor (ADNF): role in embryonic growth and prevention of HIV envelope protein-induced growth retardation. *Reg. Peptides* 71: 112, 1997.
123. Spong, C.Y., Lee, S.I., McCune, S.K., Gibney, G., Castellon, R., Brenneman, D.E. and Hill, J.M. Vasoactive intestinal peptide mRNA, peptide immunoreactivity and binding sites in mouse embryo and extraembryonic membranes. *Reg. Peptides* 71: 135, 1997.
124. Zamostiano, R., Basson, M., Davidson, A., Pitman, J., Hauser, J., Wollman, Y., Brenneman, D.E. and Gozes, I. Stress response proteins are increased and secreted from neurons and glia in the presence of VIP. *Reg. Peptides* 71: 145, 1997.
125. Giladi, E., Davidson, A., Perl, O., Ashur-Fabian, O., Bachar, M., Badrda, A., Rubinraut, S., Brennmena, D.E., Fridkin, M. And Gozes, I. Protection against developmental retardation in apolipoprotein E-deficient mice by stearyl-Nle17-VIP: implications for early treatment of Alzheimer's disease. *Reg. Peptides* 71: 149, 1997.
126. McCune, S.K., Hill, J.M., Lee, S.J., Servoss, S.J., Bassan, M., Zamostiano, R., Davidson, A., Gozes, I. And Brenneman, D.E. Localization of mRNA for Activity-Dependent Neurotrophic Facotr III (ADNF III) in mouse embryos and adult CNS. *Soc. Neurosci. Absts.* 23:2249, 1997.
127. Glazner, G.W., Brenneman, D.E., Gozes, I. And Mattson, M.P. A 9 amino acid peptide fragment of activity-dependent neurotrophic factor (ADNF) protects neurons from oxidative stress-induced death. *Soc. Neurosci. Absts.* 23:2249, 1997.
128. Beni-Adani, L., Pomeranz, S., Gozes, I., Bassan, M., Brenneman, D.E. and Shohami, E. The neuroprotective effect of activity dependent neurotrophic protein in mice after closed head injury. *Neurosci. Letters Suppl.* 48: S9-S10, 1997.
129. Ashur-Fabian, O., Giladi, E., Brenneman, D.E. and Gozes, I. Molecular identification of the VIP/PACAP neuroprotection receptor. *Neurosci. Letters. Supple.* 48:S4, 1997.

130. Giladi, E., Davidson, A., Bachar, M. Bardea, A., Rubinraut, S., Fridkin, M., Brenneman, D.E. and Gozes, I. Protection against developmental and learning impairments in apolipoprotein E-deficient mice by activity-dependent femtomolar-acting peptides. *Neurosci. Letters. Suppl.* 48:S19, 1997.

131. Zamostiano, R., Bassan, M., Davidson, A., Brenneman, D.E. and Gozes, I. A human homologue for activity-dependent neuroprotective protein. *Neurosci. Letters* Suppl. 48:S54, 1997.

132. Gozes, I., Bassan, M., Zamostiano, R., Davidson, A., Perl, O., Bassan, H., Blat, C., Giladi, E., Gibney, G., Glazner, G. And Brenneman, D.E. A femtomolar-acting activity-dependent neuroprotective protein. *Neurosci. Letters Suppl.* 48:S21, 1997.

133. Gozes, I., Bassan, M., Zamostiano, R., Davidson, A., Pinchasov, V., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G. and Brenneman, D.E. Cloning of novel super active neuroprotective proteins. *J. Neurochem.* 71(suppl. 1): S53, 1998.

134. Pelsman, A., Fernandez, G., Gozes, I., Brenneman, D.E. and Busciglio, J. Activity-dependent neurotrophic factor peptides prevent degeneration of Down's syndrome neurons grown in culture. *J. Neurochem.* 71:S54, 1998.

135. Brenneman, D.E., Hauser, J., Davidson, A. and Gozes, I. A femtomolar-acting neuroprotective peptide. *J. Neurochem.* 71 (suppl. 1): S54, 1998.

136. McCune, S.K., Spong, C.Y., Brenneman, D.E. and Hill, J.M. PACAP receptors in the developing mouse CNS. *Soc. Neurosci. Absts.* 24:299, 1998.

137. Glazner, G.W., Boland, A., Dress, D., Brenneman, D.E., Gozes, I and Mattson, M.P. ADNF-9 protects neurons against oxidative stress-induced death by activation of the transcription factor NF- $\kappa$ B. *Soc. Neurosci. Absts.* 24:1043, 1998.

138. Beni-Adani, L., Pomeranz, S., Bassan, M., Gibney, G., Brenneman, D.E. , Gozes I. and Shohami, E. Activity dependent neurotrophic protein is neuroprotective in a mouse model of closed head injury. *Soc. Neurosci. Absts.* 24:1043, 1998.

139. Pelsman ,A. Fernandez, G., Gozes, I., Brenneman, D.E., and Busciglio, J. In vitro degeneration of Down Syndrome neurons is prevented by activity-dependent neurotrophic factor peptides. *Soc. Neurosci. Absts.* 24: 1044, 1998.

140. Zamostiano, R., Bassan, M., Giladi, E., Davidson, A., Wollman, Y., Pitman, J., Hauser, J., Gibney, G., Castellon, R., Brenneman, D.E. and Gozes, I. VIP and ADNF-9 influence intercellular and extracellular heat shock proteins. *Soc. Neurosci. Absts.* 24:1044, 1998.

141. Hauser, J., Phillips, T.M., Gozes, I. and Brenneman, D.E. Activity dependent neurotrophic factor releases cytokines from astroglia. *Soc. Neurosci. Absts.* 24:1044, 1998.

142. Brenneman, D.E. Hauser, J., Gozes, I. and Phillips, T.M. Vasoactive intestinal peptide and activity dependent neurotrophic factor release chemokines from astroglia. *Soc. Neurosci. Absts.* 24:1044, 1998.

143. Spong, C.Y., Lee, S.J., McCune, S.K., Brenneman, D.E. and Hill, J.M. Neurotrophic factors activity dependent neurotrophic factor and early pregnancy factor: regulation of mRNA for VIP, IGF-1 and EPF during embryogenesis. *Soc. Neurosci. Absts.* 24:1044, 1998.

144. Hill, J.M., Lee, S.J., Gibney, G., Gozes, I., Abebe, D.T., Glazner, G. And Brenneman, D.E. Activity-dependent neurotrophic factor peptides regulate brain and body growth in the prenatal mouse. *Soc. Neurosci. Absts.* 24:1044, 1998.

145. Gozes, I., Zamostiano, R., Bassan, M., Pinchasov, A., Giladi, E. and Brenneman, D.E. The human cDNA of a femtomolar-acting activity-dependent neuroprotective protein. *Soc. Neurosci. Absts.* 24:1045, 1998.

146. Sasner, M., Hauser, J., Brenneman, D.E. and Buonanno, A. Transcriptional regulation of NMDA receptor NR2 subunits by neural input. *Soc. Neurosci. Absts.* 24: 1086, 1998.

147. Brenneman, D.E., Hauser, J., Phillips, T.M. VIP and PACAP release chemokines: a mechanism for neuroprotection from HIV envelope protein toxicity. *Regulatory Peptides* 83: 42, 1999.

148. Gozes, I., Pert, O., Giladi, E., Ashur-Fabian, O., Steingart, R.A., Sigalov, A., Brenneman, D.E., Rubinraut, S. And Fridkin, M. Mapping a VIP/PACAP active site to stearyl-KKYL-NH2: short lipophilic peptides providing broad neuroprotection. *Regulatory Peptides* 83: 47, 1999.

149. Gozes, I., Zamostiano, R., Pinhasov, A., Bassan, M., Giladi, E., Steingart, R.A., Brenneman, D.E. A novel VIP-responsive stress-defense gene: activity-dependent neuroprotective protein (ADNP). *Regulatory Peptides* 83: 47, 1999.

150. Hill, J.M., Castellon, R., Mehnert, J.M., Phillips, T.M. and Brenneman, D.E. Vasoactive intestinal peptide releases trophic factors from the embryonic neuroepithelium. *Regulatory Peptides* 83: 49, 1999.

151. Steingart, R.A., Solomon, B., Brenneman, D.E., Fridkin, M. and Gozes, I. VIP and activity-dependent neurotrophic factor protect against oxidative stress in PC12 cell culture. *Neuroscience Letters* 54: S39, Suppl. Nov, 1999.

152. Sigalov, E., Steingart, R.A., Fridkin, M., Brenneman, D.E. and Gozes, I. Protection by neuropeptides against ischemic/hypoxic injury. *Neuroscience Letters* 54: S38, Suppl. Nov, 1999.

153. Leker, R.R., Teichner, A., Grigoriadis, N., Brenneman, D.E., Gozes, I. The octapeptide NAP exerts neuroprotection in a model of focal cerebral ischemia by reducing apoptosis. *Neuroscience Letters* 54: S26, Suppl. Nov, 1999.

154. Ashur-Fabian, O., Sigalov, E., Brenneman, D.E., Gozes, I. NAP, a superactive neuroprotective peptide increases NO production in neuro-glial cells. *Neuroscience Letters* 54: S3, Suppl. Nov, 1999.

155. Gozes, I., Zamostiano, R., Pinhasov, A., Bassan, M., Gilai, E., Steingart, R.A. and Brenneman, D.E. A novel VIP responsive gene: activity-dependent rroprotective protein (ADNP). *Neuroscience Letters* 54: S18, Suppl. Nov, 1999.

156. Moody, T., Casiband, M., Leyton, J., Brenneman, D.E., Fridkin, M., Gelber, E., Levi, A., and Gozes, I. VPAC1 receptors and lung cancer. *Regulatory Peptides* 83:54, 1999.

157. Brenneman, D.E., Hauser, J. and Phillips. T.M. Chemokine release from astrocytes: regulation by vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide. *Soc. Neurosci. Absts.* 25: 567, 1999.

158. Gozes, I., Steingart, R.A., Sigalov, E., Bassan, M., Zamostiano, R., Fridkin, M., Brenneman, D.E., Ovaia, H. and Leker, R. VIP and associated peptides provide protection against ischemia and oxidative stress. *Soc. Neurosci. Absts.* 25: 756, 1999.

159. Spong, C.Y., Abebe, D., Gozes, I., Brenneman, D.E. and Hill, J.M. Prevention of fetal alcohol syndrome with ADNF-like peptides. *Soc. Neurosci. Absts.* 25: 1009, 1999.

160. McCune, S.K., Rivera, O., Abebe, D., Hill, J.M., Brenneman, D.E. and Phllips, T.M. Chronic intrauterine hypoxia causes fetal growth retardation and profound alterations in cytokines and growth factor expression. *Soc. Neurosci. Absts.* 25: 1536, 1999.

161. Hill, J.M., Castellon, R., Mehnert, J.M., Phllips. T.M. and Brenneman, D.E. Secretory actions of VIP in the embryonic neural tube. *Soc. Neurosci. Absts.* 25: 2026, 1999.

162. Zamostiano, R., Pinhasov, A., Bassan, M., Giladi, E., Steingart, R.A., Busicilgio, J., Brenneman, D.E. and Gozes, I. Activity-dependent neuroprotective protein (ADNP): a putative VIP-responsive stress-defense gene. *Soc. Neurosci. Absts.* 25:2026, 1999.

163. Auth, J., Moody, E., Varner, M., Brenneman, D.E. and Spong, C.Y. Midtrimester amniotic fluid macrophage inflammatory protein-1 alpha: not a predictor of poor pregnancy outcome. *Am. J. Obstet. Gynecol.* 180: S102: 2000.

164. Spong, C.Y., Degrado, L., Varner, M., Belfort, M., Pezzullo, J.C., Ghidini, A., Brenneman, D.E., Phillips, T.M. Evaluation of a panel of cytokines, chemokines, neuropeptides in a single aliquot of midtrimester amniotic fluid in the prediction of fetal growth restriction. *Am. J. Obstet. Gynecol.* 180:S107, 2000.

165. Brenneman, D.E., Hauser, J., Spong, C.Y., Phillips, T.M. Pituitary adenylate cyclase activating peptide regulates chemokine release: implications for neuroprotection against HIV envelope protein toxicity. *Regulatory Peptides* 86: 25, 2000.

166. Gozes, I., Ashur-Fabian, O., Furman, S., Steingart, R.A., Sigalov, E., Pinhasov, A., Bassan, M., Zamostiano, R., Perl, O., Rubinraut, S., Fridkin, M. and Brenneman, D.E. Neuropeptide-based drug design. *Regulatory Peptides* 86: 26, 2000.

167. McCune, S.K., Rivera, O., Abebe, D., Hill, J.M., Brenneman, D.E. and Phillips, T.M. Profound alterations in cytokine and growth factor peptides in chronic intrauterine hypoxia with fetal growth retardation: CE analysis. *Regulatory Peptides* 86: 44, 2000.

168. Hill, J.M., Phillips, T.M and Brenneman, D.E. The neuropeptides VIP and PACAP regulate cytokine and growth factor secretion in the embryonic neural tube. *Regulatory Peptides* 86: 45, 2000.

169. Brenneman, D.E., Bassan, M., Spong, C.Y. and Gozes, I. Protective peptides derived from novel glial proteins. *Biochem. Soc. Trans.* 28:A61, 2000.

170. McCune, S.K., Rivera, O., Abebe, D.T., Hill, J.M., Brenneman, D.E. and Phillips, T.M. Chronic in utero hypoxia causes fetal growth retardation and profound alterations in CNS cytokine and growth factor expression. *Pediatric Res.* 47:(4)435, Suppl. S, Apr., 2000.

171. Ades, A.M., McCune, S.K., Crnic, L.S., Ring, M., Brenneman, D.E. and Hill, J.M. Vasoactive intestinal peptide dysfunction associated with a segmental trisomy model of Down syndrome. *Pediatric Res.* 47:(4)472, Suppl. S Apr. 2000.

172. Smith-Swintosky, V.L., Gozes, I., Brenneman, D.E., Plata-Salaman, C. Activity-dependent neurotrophic factor-9 (ADNF-9) and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. *Soc. Neurosci. Absts.* 26: 843, 2000.

173. Gozes, I., Giladi, E., Pinhasov, A., Golian, T., Romano, J. and Brenneman, D.E. Activity-dependent neurotrophic factor (ADNF): comparison of intranasal and oral administration of femtomolar-acting L- and D- peptides to improve memory. *Soc. Neurosci. Absts.* 26: 588, 2000.

174. Abebe, D.T., Auth, J., Moody, E., Gozes, I., McCune, S.K., Brenneman, D.E. and Spong, C.Y. In utero treatment with protective peptides prevent alcohol-induced activity alterations in adult male mice. *Soc. Neurosci. Absts.* 26:588, 2000.

175. Spong, C.Y., Abebe, D.T., Gozes, I. and Brenneman, D.E. All D-amino acid peptides prevent fetal death in a mouse model of fetal alcohol syndrome. *Soc. Neurosci. Abst.* 26:588, 2000.

176. Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R., Giladi, E., Bassan, M., Hauser, J., Wollman, Y., Eyre, H.J., Mulley, J.C., Seroussi, E., Brenneman, D.E. and Gozes, I. Cell proliferation inhibition by oligodeoxynucleotides complementary to activity-dependent

neuroprotective protein (ADNP) mapped to a chromosomal region amplified in cancer. *Soc. Neurosci. Absts.* 26: 588,2000

177. Blondel, O., Collin, C., McCarran, W., Zhu, X., Zamostiano, R., Gozes, I., Brenneman, D.E., McKay, R.D.G. ADNF: a glial-derived signal regulating neuronal differentiation. *Soc. Neurosci. Absts.* 26: 588, 2000.

178. Hill, J.M., Mehnert, J., Brenneman, D.E. VIP and PACAP regulation of NGF in the E9.5 mouse embryo neural tube. *Soc. Neurosci. Absts.* 26: 586,2000.

179. Brenneman, D.E., Hauser, J. And Gozes, I. Neuroprotective peptides that exhibit both synergistic and non-chiral characteristics in dissociated cerebral cortical test cultures. *Soc. Neurosci. Absts.* 26:588, 2000.

180. Spong, C.Y., Abebe, D.T., Gozes, I., Brenneman, D.E. and Hill, J.M. Prevention of fetal death with novel peptides in fetal alcohol syndrome. *Am. J. Obst. Gynecol.* 182:15, 2000.

181. Hill, J.M., Mehnert, J., Phillips, T.M., and Brenneman, D.E. VIP and PACAP regulation of growth factors/cytokines in E9.5 mouse embryo neural tube. *Regulatory Peptides* 89: 64, 2000.

182. Spong, C.Y., Abebe, D., Auth, J., Gozes, I., Hill, J.M. and Brenneman, D.E. Peptides prevent alcohol-induced fetal death, biochemical alterations and leaning problems. *Regulatory Peptides* 89: 82, 2000.

183. Brenneman, D.E., Hauser, J., Ades, A., Hill, J.M., Ring, M., McCune, S.K., Crnic, L.S. and Phillips, T.M. VIP-mediated interactions with cerebral cortical cultures derived from partial trisomy 16 (Ts65Dn) mice: implications for Alzheimer's disease. *Regulatory Peptides* 89: 55, 2000.

184. Brenneman, D.E., Spong, C.Y., Hauser, J., Gozes, I. Neuroprotective peptides prevent neuronal and embryonic death. *Abst. Of Am. Chem. Soc.* 219:315, 2000.

185. McCune, S.K., Brenneman, D.E. and Hill, J.M. Expression profile of signal transduction and cytokine genes in control and VIP-stimulated E9.5 neural tubes. *Soc. Neurosci. Absts.* 27: 138.7, 2001.

186. Brenneman, D.E., Hauser, J.M., Phillips, T.M. and Gozes, I. Neurotrophic peptides (NAP and ADNF-9) produce cytokine and chemokine secretion in cultured astrocytes. *Soc. Neurosci. Absts.* 27: 364.4, 2001.

187. Gozes, I., Zaltzman, R., Alcalay, R., Romano, J., Giladi, E., Beni-Adani, L., Beni, S., Hill, J.M., Leker, R.R., Shohami, E. And Brenneman, D.E. NAP, a peptide derived from activity-dependent neuroprotective protein, provide a broad range of long-term neuroprotection. *Soc. Neurosci. Absts.* 27:364.5, 2001.

188. Hill, J.M., Hauser, J.M., Furman, S., Gozes, I., Brenneman, D.E. Localization of Activity-dependent neuroprotective protein-like immunoreactivity in the neonatal rat brain. Soc. Neurosci. Absts. 27: 364.7, 2001.

189. Hauser, J.M., Gozes, I., Furman, S., Giladi, E., Rubinraut, S., Fridkin, M., Spong, C.Y., Brenneman, D.E. Neuroprotective peptide exhibits stability in vivo and in vitro. Soc. Neurosci. Abst. 27:364.8, 2001.

## AWARDS & Honors

1. Bond Award - Best technical paper contributed at national meeting of American Oil Chemists' Society.
2. Fellowship for graduate study from Lilly Pharmaceutical Company.
3. Newmark Award - Outstanding biochemical research, University of Kansas.
4. Speaker representing all doctoral students for the Ph.D. Hooding Ceremony, University of Kansas.
5. PRAT (Pharmacology Research Associate Trainee)- Fellowship for postdoctoral training at NIGMS (1980-81).
6. Intramural Research Grant for AIDS structural biology initiative (1987-88).
7. Equal Employment Opportunity Special Achievement Award, NICHD, 1989.
8. United States-Israel Binational Science Foundation Research Grant with Dr. Illana Gozes on Activity Dependent Neurotrophic Factor; 1992-1995.
9. Guest Editor for Journal of Molecular Neuroscience. Special Topic: Neuropeptides as Growth Factors, 1993
10. NIH Merit Award, 1993
11. NIH Director's Award, 1997.
12. Collaborative Research Agreement for ADNF research, Pfizer Corporation, Tel Aviv University and NICHD. (1997-1998).
13. United States-Israel Binational Science Foundation Research. Grant with Dr. Illana Gozes on ADNF III. 1997-1999.
14. Editorial Board for the Journal Neuropeptides 1998-
15. Scientific Advisory Board for the 4th International Symposium on VIP, PACAP, Glucagon and related peptides. 1998
16. Appointed to Steering Committee for the Winter Neuropeptide Conference, 1998-
17. Editorial Board for the Journal of Molecular Neuroscience 1999-

18. Election as permanent member of the International Organizing Committee for the Symposium on VIP, PACAP, Glucagon and related peptides. 1999-present
19. United States-Israel Binational Science Foundation Research. Grant with Dr. Illana Gozes on ADNP. 2000-2002.
20. The 2000 Neufeld Memorial Research Grant Award. This award is given annually to the most outstanding and original Binational Science Foundation-supported project in the health sciences. Co-recipient with Dr. Gozes for the ADNP Grant.

**U.S. and Foreign Patents Pending or Awarded**

1. Activity Dependent Neurotrophic Factor, Brenneman and Gozes, 1990  
U.S. Patent awarded, Issued June 16, 1998. Patent No. 5,767,240.
2. VIP receptor antagonist, Gozes, Moody, Fridkin and Brenneman, 1991.  
U.S. Patent No. 5,217,953
3. Superactive VIP Antagonists. Gozes, Brenneman, Fridkin and Moody, 1994.  
U.S. Patent No. 5,565,424, Awarded on October 15, 1996.
4. Neurotrophic peptides of ADNF. Brenneman and Gozes, Inventors  
U.S. Patent No. 6,174,862 B1. Awarded January 16, 2001.
5. Activity Dependent Neurotrophic Factor Brenneman and Gozes, 1992  
Australian Patent No. 21680/92
6. Brenneman, D.E. and Gozes, I. Activity Dependent Neurotrophic Factor. European Patent No. 92913651.3
7. Mouse cDNA Structure of a Novel Neurotrophic Protein: Activity Dependent Neurotrophic Factor III: Identification of a core 8 Amino Acid Neurotrophic Peptide. Gozes, Brenneman, Basan, Zamostiano, 1997. Patent pending
8. Orally active peptides that prevent cell injury and death. Brenneman, Spong, Gozes, Pinhasov and Giladi. Patent pending 1999 60/149,956.
9. Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides. Brenneman, Spong, Gozes, Bassan and Zamostiano. Patent pending 1999.

10. Neurotrophic peptides of ADNF, Nov. 4, 1999, Australian Patent No. 707838
11. Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides. Gozes, Brenneman, Zamostiano, Gelber, Pinhasov, Bassan. 1999 Patent pending.
12. Combination Therapy with VIP Antagonist. Gozes, Moody, Brenneman, Fridkin, Gelber and Levy. 1999 Patent Pending.
13. Vasoactive intestinal peptide derived lipophilic conjugates for treatment of skin disorders. Gozes, Granoth, Fridkin and Brenneman 2000 Patent pending No. 136631
14. Novel peptides enhance performance in spatial learning. Gozes, Giladi, Spong and Brenneman 2000 Patent pending
15. Human Activity-Dependent Neurotrophic Factor III (ADNF III) Gozes, Brenneman, Basan, Zamostiano. U.S application 09/267,411
16. Superactive VIP Antagonists Moody, Gozes, Brenneman and Fridkin. European Patent No. 0738280 Granted 2/14/2001.
17. Neurotrophic peptides of the ADNF Complex. Brenneman, Gozes, Castellon, and Spong. 9/1/01.

#### Membership in Professional Organizations

1. American Association for the Advancement of Science
2. Society for Neuroscience
3. International Society for Developmental Neuroscience
4. American Society for Pharmacology and Experimental Therapeutics

#### Membership in NIH Committees

1. NICHD Safety Committee (Chairman) (1990-1997 )
2. ICD Safety Committee (1990-1997)
3. NIH Occupational Safety and Health Committee (1990-1994)
4. Laboratory and Animal Users Committee for Building 49 (1994-95)

5. Howard Hughes Medical Scholar Selection Committee (1996-1998)
6. NICHD Animal Care and Use Committee (2000-present)

#### Invitations for Presentations

1. 1982 University of Illinois Department of Anatomy
2. 1982 University of Indiana Department of Pharmacology
3. 1982 Sandoz Pharmaceutical Co. Toxicology Department
4. 1983 Louisiana State University Department of Pharmacology
5. 1983 Georgetown University Department of Biology
6. 1984 Society for Neuroscience Los Angeles, CA.
7. 1984 FASEB Summer Research Conference on Cell Cultures
8. 1985 Johns Hopkins University Department of Neuroscience.
9. 1985 Canadian Federation of Biological Societies. Symposium on Cholinergic Neurons.
10. 1985 Winter Neuropeptide Conference in Breckenridge Colo. Symposium on Neuropeptides as regulators of development.
11. 1986 George Washington University Department of Biochemistry.
12. 1987 New York Academy of Sciences. Conference on Vasoactive intestinal peptide.
13. 1987 NICHD Centennial Symposium on Neurodevelopment
14. 1987 Society of Neuroscience. Chairman of session on Neuronal Cell Death.
15. 1988 Winter Brain Conference. Symposium on Neuron-Glia interactions. Steamboat Springs, Colo.
16. 1988 American Society for Microbiology. Symposium on CNS manifestations of HIV infection. Miami, Florida.
17. 1988 Winter Neuropeptide Conference. Symposium on Neurotrophic peptides. Breckenridge, Colo.

18. 1988 American Society for Pharmacology and Experimental Therapeutics. Symposium on Neuropeptides as regulators of mitosis: clinical implications. Las Vegas, Nevada.
19. 1988 UCLA conference on neural-immune interactions. Symposium on HIV and the nervous system. Lake Tahoe, CA
20. 1988 International Society for Developmental Neuroscience. Symposium on synapse formation and elimination. Jerusalem, Israel.
21. 1988 International Society for Developmental Neuroscience. Symposium on Ontogeny of Neuropeptides. Jerusalem, Israel.
22. 1988 XVIthe Collegium Internationale Neuro-Psychopharmacologicum. Symposium on AIDS. Munich, Federal Republic of Germany.
23. 1989 Winter Brain Conference. Symposium on AIDS and the nervous system. Snowbird, Utah.
24. 1989 American Society of Neurochemistry. Symposium on neuron-glial interactions. Chicago, Ill.
25. 1989 4th International Conference on VIP. Talk on glial proteins and VIP. Stockholm, Sweden.
26. 1990 University of Alabama/NICHD Conference on Environmental Determinants of Nervous system Development. Co-organizer of session on Molecular and Cellular Developmental Mechanisms. Birmingham, Alabama.
27. 1990 Society for Neuroscience symposium on Growth Factors and Glia. St. Louis, Mo.
28. 1990 Chicago Lung Association. Talk on interactions between neuropeptides and cytokines. Chicago, Ill.
29. 1991 Winter Brain Conference Symposium on neurotoxic effects of gp120, the envelope protein of HIV. Vail, Colorado.
30. 1991 Sixth Annual Christian Anfinsen Seminar Series in the Neurosciences. Talk on regulation of neuronal cell death during development. NIH.
31. 1991 Satellite Symposium on PACAP. Co-organizer of an international symposium on PACAP, chairman of session on PACAP physiology, and talk on developmental effects of PACAP. New Orleans, Louisiana.
32. 1991 Department of Anatomy, West Virginia University School of Medicine. Talk on VIP as a mediator of neuron-glia interactions.

33. 1991 Workshop on Neuro-AIDS: drug discovery and development sponsored by NIAID. Talk on gp120 neurotoxicity. Portland, Maine.

34. 1992. Department of Biological Science, Rutgers University  
Talk on Permissive glial-derived growth factors.

35. 1992. Pharmavene Corp., New York City, Talk on Activity Dependent Neurotrophic Factor.

36. 1992. Symposium on Neuropeptides as Developmental Cues. Winter Neuropeptide Conference, Breckenridge, Colo.

37. 1992, Faculty of Medicine Lecture on Neuron-Glial interactions. Tel Aviv University, Tel Aviv, Israel.

38. 1992. Plenary Talk on NeuroAIDS at Israel Society for Clinical Biochemistry, Haifa, Israel.

39. 1992. Synergen Corp. Talk on Activity Dependent Neurotrophic Factor., Boulder, Colorado.

40. 1992. Psychoneuroimmunology Program, UCLA, Talk on the developmental and pathological aspects of cytokines in the brain. Los Angles, California.

41. 1992. Symposium on Mechanisms of Neurological Damage in AIDS. Society of Neuroscience, Anaheim, California.

42. 1992. Second Workshop on Neuro-AIDS. Talk on Toxic Fragments of Gp120., Portland, Maine.

43. 1992. Neurology Department. Johns Hopkins School of Medicine. Talk on Neurotoxicity of gp120 in vitro and in vivo. Baltimore, MD.

44. 1992. Symposium on Activity and Neuronal Development. International Society for Developmental Neuroscience., Montpelier, France.

45. 1993 Symposium on the Neurological aspects of cytokines. American Society for Neurochemistry, Richmond, VA.

46. 1993 Symposium on the Neurotrophic Actions of Cytokines. International Society for Neurochemistry, Montpelier, France.

47. 1993 Department of Pharmacology. University of Kansas, Talk on Molecular pharmacology of VIP neurotrophism. Lawrence, Kansas.

48. 1993 Symposium on PACAP and VIP as regulatory molecules, 14th Annual Winter Neuropeptide Conference, Breckenridge, Colorado.

49. 1993 Learning Disabilities Society. Talk on Multidisciplinary approaches to developmental toxicology. San Francisco, California.

50. 1993 Symposium on VIP functions in the Brain, First International meeting on PACAP, VIP and related peptides. Strasbourg, France.

51. 1993 Symposium on Growth Factors and Neuronal Cell Death. Israeli Society for Clinical Biochemistry and Tel Aviv University, Tel Aviv, Israel.

52. 1993 Department of Neuroscience. University of Miami Medical School. Talk on Activity Dependent Neurotrophic Factor. Miami, Florida.

53. 1993 Third annual Neuro-AIDS conference sponsored by NIAID. Talk on activity dependent neurotrophic factor and gp120-induced neurotoxicity. Portland, Maine.

54. 1993 European Neuroendocrine Association. Symposium on Neuropeptides and Growth Factors. Lisboa, Portugal.

55. 1994. Symposium on cytokines in the nervous system. FASEB Summer Research Conference, Cooper Mountain. Colorado.

56. 1994. Chairman of Symposium on Growth Factors and cytokines at International Conference on Growth Factors, Hormones and Drug Design, Israeli Ministry of Science and Arts. Talk on Activity dependent neurotrophic factor. Tiberius, Israel.

57. 1994. Organizing Committee for Second International Symposium on VIP, PACAP and related peptides. New Orleans, LA.

58. 1994 Chairman of Symposium on Neurotrophic Peptides and Peripheral Nerve Regeneration. 15 th Annual Winter Neuropeptide Conference. Talks on Neuropeptide Drug Design and Neuropeptide regulation of embryonic growth. Breckenridge, Colorado.

59. 1994. Symposium on Neurotrophic peptides and Drug Design. Summer Neuropeptide Conference. Martha's Vineyard, MA.

60. 1994. Talk on VIP antagonist producing microcephaly. European Society for Neurochemistry. Jerusalem, Israel.

61. 1994. Chairman of Session on 'Neuropeptides, their antagonists and drug development. European Society for Neurochemistry. Jerusalem, Israel.

62. 1994. Chairman of Symposium on Cytokine-Neuropeptide interactions at Summer FASEB conference on Neuro-Immune Interactions. Cooper Mountain, Colorado.

63. 1995. Talk on identification of a femtomolar acting neuroprotective peptide. International Society for Neurochemistry. Kyoto, Japan.

64. 1995. Talk on VIP as a regulator of embryonic growth. Satellite meeting on VIP, PACAP and related peptides, International Society for Neurochemistry. Osaka, Japan.

65. 1995. Talk on Activity Dependent Neurotrophic Factor. Pfizer Corp. Groton, Connecticut.

66. 1995. Symposium talk on Mechanism of peptide T-mediated neuroprotection in AIDS. 16th Annual Winter Neuropeptide Conference, Breckenridge, Colorado.

67. 1995. Plenary speaker on Neuropeptide Regulation of Embryonic Development. European Society for Neurochemistry. Jerusalem, Israel.

68. 1995. Talk on Activity Dependent Neurotrophic Factor. Department of Neuroscience. Beijing Medical University, Beijing, China.

69. 1995 Talk on Mechanism of neuroprotection of VIP analogues against NeuroAIDS. Department of Physiology, Georgetown University Medical School.

70. 1996. Symposium Chairman on Mechanisms of VIP and PACAP regulated growth. Winter Neuropeptide Meeting, Breckenridge, Colorado.

71. 1996. Talk on Pharmacology of VIP mediated secretion of glia-derived cytokines. Winter Neuropeptide Meeting, Breckenridge, Colorado.

72. 1996. Talk of VIP mediated regulation of neuronal survival and embryonic growth. Keystone meeting on Neural peptides, Lake Tahoe, California.

73. 1996. Talk on Activity Dependent Neurotrophic Factor. R.T. Johnson Pharmaceutical Research Institute. Philadelphia, PA.

74. 1996. Talk on VIP neurotrophic action mediated by an extracellular stress protein. Summer Neuropeptide Meeting. Martha's Vineyard, Massachusetts.

75. 1996. Talk on A femtomolar activity neuroprotective peptide at Cold Spring Harbor Meeting on the Heat Shock Response and Chaperonins. Cold Spring Harbor, New York.

76. 1996. Talk on Femto-Neurobiology: from CNS ontogeny to Therapeutic Strategy. University of Nebraska Medical School. Omaha, Nebraska.

77. 1997. Talk on Neurotrophic peptides at European Neuropeptide Conference, Kitzbuhel, Austria.

78. 1997. Talk on Activity Dependent Neurotrophic Factor at International Congress on Stress. Budapest, Hungary.

79. 1997. Talk on Activity Dependent Neurotrophic Factor at Biogen Corporation, Boston, MA.

80. 1997. Talk on Neuron-Glia interactions at the International Symposium on Signal Transduction in Health and Disease. Tel Aviv, Israel.

81. 1997. Chairman of session on VIP agonists and antagonists. Third International Symposium on VIP, PACAP and Related Peptides. Freiburg, Germany.

82. 1997. Talk on a femtomolar-acting neuroprotective peptide. Third International Symposium on VIP, PACAP and Related Peptides. Freiburg, Germany.

83. 1997. Talk on activity dependent neurotrophic factor. Department of Neuroscience. University of Maryland. Baltimore, MD

84. 1998. Talk on Neuropeptide-Chemokine interactions that mediate neuroprotection. 19th Annual Winter Neuropeptide Conference, Breckenridge, Colorado.

85. 1998. Talk on Mechanisms of ADNF Neuroprotection. Symposium at European Neurochemistry Society. St. Petersburg, Russia.

86. 1998. Co-chairman of session on Growth factors in neurodevelopment and aging: potential new therapies. 12th Meeting of the European Neurochemistry Society, St. Petersburg, Russia.

87. 1999 Plenary Lecture on VIP neurotrophic mechanisms at the 20th Annual Winter Neuropeptide Conference. Breckenridge, Colorado.

88. 1999 Talk on Chemokines as mediators of VIP neuroprotection. 4th International Symposium on VIP, Glucagon and Related Peptides. Copenhagen, Denmark.

89. 1999 Chairman of the session on Development and Neurotrophic actions of VIP and PACAP. 4th International Symposium on VIP, Glucagon and Related Peptides. Copenhagen, Denmark.

90. 2000 Chairman of Symposium on Neuropeptides and Neuroprotection 21st Annual Winter Neuropeptide Conference. Breckenridge, Colorado.

91. 2000 Talk on PACAP-mediated release of chemokines. 21st Annual Winter Neuropeptide Conference. Breckenridge, Colorado.

92. 2000 Co-Chairman of Young Investigators Symposium. 21st Annual Winter Neuropeptide Conference. Breckenridge, Colorado.

93. 2000 Talk on ADNF-mediated neuroprotection. Indiana University School of Medicine. Indianapolis, Indiana.

94. 2000 Talk on Functional VIP deficits in astroglia derived from trisomy mice. European Neuropeptide Conference. Innsbruck, Austria

95. 2000 Talk on Peptide prevent fetal death in pregnant mice treated with alcohol. Sackler School of Medicine, Tel Aviv University.

96. 2000 Talk on Femtomolar-acting neuroprotective peptides. American Chemical Society. San Francisco, California.

97. 2000 Talk on Protective Peptides derived from Novel Glial Proteins. Biochemical Society. Leeds, United Kingdom.

98. 2000 Talk on Neuropeptides and Neuroprotection in the central nervous system. Neuroscience Department. Uniform Services Medical School. Bethesda, Maryland.

99. 2000 Chairman and organizer of Session on Cytokines and Neurodegenerative Disease. Satellite meeting to the Society for Neuroscience. New Orleans, Louisiana.

100. 2000 Talk on Cytokine Release from Astrocytes derived from partial trisomy mouse brain. Cytokines and Brain 2 symposium. New Orleans, Louisiana.

101. 2001 Co-organizer of 22nd annual meeting of the Winter Neuropeptide Conference. Breckenridge, Colorado.

102. 2001 Member of International Advisory Committe to the Neuropeptide 2001 Meeting. Kibbutz Ma'le Hachamisha, Israel.

103. 2001 Talk on Novel Peptide Mediators of VIP-associated neuronal survival: potential leads for drug design. At Peptide Receptors Symposium Montreal 2001 Montreal, Canada

104. 2001 Sam Hersch Symposium on Cerebral Palsy. Talk on neuroprotective peptide agonists from ADNF and ADNP. Salk Institute, San Diego, CA.